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reamble
primary challenge in the development of clinical practice
idelines is keeping pace with the stream of new data on
hich recommendations are based. In an effort to respond
omptly to new evidence, the American College of Cardi-
ogy Foundation/American Heart Association (ACCF/AHA)
ask Force on Practice Guidelines (Task Force) has created a
ocused update” process to revise the existing guideline
commendations that are affected by the evolving data or
inion. Before the initiation of this focused approach,
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UA/NSTEMI Guideline Focused Update May 10, 2011:1920–59riodic updates and revisions of existing guidelines required
to 3 years to complete. Now, however, new evidence will
reviewed in an ongoing fashion to more efficiently respond
important science and treatment trends that could have a
ajor impact on patient outcomes and quality of care.
vidence will be reviewed at least twice a year, and updates
ill be initiated on an as-needed basis and completed as
ickly as possible while maintaining the rigorous method-
ogy that the ACCF and AHA have developed during their
rtnership of more than 20 years.
These updated guideline recommendations reflect a con-
nsus of expert opinion after a thorough review, primarily of
te-breaking clinical trials identified through a broad-based
tting process as being important to the relevant patient
pulation, as well as other new data deemed to have an
pact on patient care (see Section 1.1, Methodology and
vidence Review, for details). This focused update is not
tended to represent an update based on a full literature
view from the date of the previous guideline publication.
pecific criteria/considerations for inclusion of new data
clude the following:
Publication in a peer-reviewed journal
Large, randomized, placebo-controlled trial(s)
Nonrandomized data deemed important on the basis of
results affecting current safety and efficacy assumptions
Strength/weakness of research methodology and findings
Likelihood of additional studies influencing current
findings
Impact on current and/or likelihood of need to develop
new performance measure(s)
Request(s) and requirement(s) for review and update from
the practice community, key stakeholders, and other
sources free of relationships with industry or other poten-
tial bias
Number of previous trials showing consistent results
Need for consistency with a new guideline or guideline
revisions
analyzing the data and developing the recommendations
d supporting text, the focused update writing group used
idence-based methodologies developed by the Task Force
at are described elsewhere (1).
The committee reviewed and ranked evidence supporting
rrent recommendations, with the weight of evidence ranked
Level A if the data were derived from multiple randomized
inical trials or meta-analyses. The committee ranked avail-
le evidence as Level B when data were derived from a
ngle randomized trial or nonrandomized studies. Evidence
as ranked as Level C when the primary source of the
commendation was consensus opinion, case studies, or
andard of care. In the narrative portions of these guidelines,
idence is generally presented in chronological order of
velopment. Studies are identified as observational, retro-
ective, prospective, or randomized when appropriate. For
rtain conditions for which inadequate data are available,
commendations are based on expert consensus and clinical
perience and ranked as Level C. An example is the use of
nicillin for pneumococcal pneumonia, for which there arerandomized trials and treatment is based on clinical reperience. When recommendations at Level C are supported
historical clinical data, appropriate references (including
inical reviews) are cited if available. For issues where
arse data are available, a survey of current practice among
e clinicians on the writing committee was the basis for
evel C recommendations and no references are cited. The
hema for classification of recommendations and level of
idence is summarized in Table 1, which also illustrates how
e grading system provides an estimate of the size and the
rtainty of the treatment effect. A new addition to the
CCF/AHA methodology is a separation of the Class III
commendations to delineate whether the recommendation
determined to be of “no benefit” or associated with “harm”
the patient. In addition, in view of the increasing number of
mparative effectiveness studies, comparator verbs and sug-
sted phrases for writing recommendations for the compar-
ive effectiveness of one treatment/strategy with respect to
other for Class I and IIa, Level A or B only have been
ded.
The Task Force makes every effort to avoid actual, poten-
al, or perceived conflicts of interest that may arise as a result
relationships with industry and other entities (RWI) among
e writing group. Specifically, all members of the writing
oup, as well as peer reviewers of the document, are asked
disclose all current relationships and those existing 12
onths before initiation of the writing effort. In response to
plementation of a newly revised RWI policy approved by
e ACC and AHA, it is also required that the writing group
air plus a majority of the writing group (50%) have no
levant RWI. All guideline recommendations require a
nfidential vote by the writing group and must be approved
a consensus of the members voting. Members who were
cused from voting are noted on the title page of this
cument and in Appendix 1. Members must recuse them-
lves from voting on any recommendation to which their
WI apply. Any writing group member who develops a new
WI during his or her tenure is required to notify guideline
aff in writing. These statements are reviewed by the Task
orce and all members during each conference call and/or
eeting of the writing group and are updated as changes
cur. For detailed information about guideline policies and
ocedures, please refer to the ACCF/AHA methodology and
licies manual (1). Authors’ and peer reviewers’ RWI pertinent
this guideline are disclosed in Appendixes 1 and 2, respec-
ely. Additionally, to ensure complete transparency, writing
oup members’ comprehensive disclosure information—in-
uding RWI not pertinent to this document—is available online
a supplement to this document. Disclosure information for the
ask Force is also available online at www.cardiosource.org/
CC/About-ACC/Leadership/Guidelines-and-Documents-Task-
orces.aspx. The work of the writing group was supported
clusively by the ACCF and AHA without commercial sup-
rt. Writing group members volunteered their time for this
fort.
The ACCF/AHA practice guidelines address patient pop-
ations (and healthcare providers) residing in North Amer-
a. As such, drugs that are currently unavailable in North
merica are discussed in the text without a specific class of
commendation. For studies performed in large numbers of
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May 10, 2011:1920–59 UA/NSTEMI Guideline Focused Updatebjects outside of North America, each writing group
views the potential impact of different practice patterns and
tient populations on the treatment effect and the relevance
the ACCF/AHA target population to determine whether the
ndings should inform a specific recommendation.
The ACCF/AHA practice guidelines are intended to assist
althcare providers in clinical decision making by describ-
g a range of generally acceptable approaches for the
agnosis, management, and prevention of specific diseases
conditions. These practice guidelines represent a consensus
expert opinion after a thorough review of the available
rrent scientific evidence and are intended to improve
ble 1. Applying Classification of Recommendation and Level o
*Data available from clinical trials or registries about the usefulness/efficacy
yocardial infarction, history of heart failure, and prior aspirin use. A recommend
any important clinical questions addressed in the guidelines do not lend them
ry clear clinical consensus that a particular test or therapy is useful or effect
†For comparative effectiveness recommendations (Class I and IIa; Level of Evi
rect comparisons of the treatments or strategies being evaluated.tient care. The guidelines attempt to define practices that reeet the needs of most patients in most circumstances. The
timate judgment regarding care of a particular patient must
made by the healthcare provider and patient in light of all
e circumstances presented by that patient. Thus, there are
rcumstances in which deviations from these guidelines may
appropriate. Clinical decision making should consider the
ality and availability of expertise in the area where care is
ovided. When these guidelines are used as the basis for
gulatory or payer decisions, the goal should be improve-
ent in quality of care. The Task Force recognizes that
tuations arise for which additional data are needed to better
form patient care; these areas will be identified within each
nce
rent subpopulations, such as sex, age, history of diabetes, history of prior
th Level of Evidence B or C does not imply that the recommendation is weak.
o clinical trials. Although randomized trials are unavailable, there may be a
and B only), studies that support the use of comparator verbs should involvef Evide
in diffe
ation wi
selves t
ive.
dence Aspective guideline when appropriate.
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UA/NSTEMI Guideline Focused Update May 10, 2011:1920–59Prescribed courses of treatment in accordance with these
commendations are effective only if they are followed.
ecause lack of patient understanding and adherence may
versely affect outcomes, physicians and other healthcare
oviders should make every effort to engage the patient’s
tive participation in prescribed medical regimens and life-
yles.
The recommendations in this focused update will be
nsidered current until they are superseded by another
cused update or the full-text guidelines are revised. This
cused update is published in the Journal of the American
ollege of Cardiology and Circulation as an update to the
ll-text guideline (2), and it is also posted on the ACC
ww.cardiosource.org) and AHA (my.americanheart.org)
orld Wide Web sites. A revised version of the full-text
ideline with links to the focused update is e-published in
e May 3, 2011, issues of the Journal of the American
ollege of Cardiology and Circulation. For easy reference,
is online-only version denotes sections that have been
dated.
Alice K. Jacobs, MD, FACC, FAHA
Chair, ACCF/AHA Task Force on Practice Guidelines
. Introduction
.1. Methodology and Evidence Review
ate-breaking clinical trials presented at the 2008 and 2009
nual scientific meetings of the ACC, AHA, and European
ociety of Cardiology, as well as selected other data through
pril 2010, were reviewed by the standing guideline writing
mmittee along with the parent Task Force and other experts
identify those trials and other key data that may impact
ideline recommendations. On the basis of the criteria/
nsiderations noted above, recent trial data and other clinical
formation were considered important enough to prompt a
cused update of the 2007 ACC/AHA Guidelines for the
anagement of Patients With Unstable Angina/Non–ST-
levation Myocardial Infarction (UA/NSTEMI) (2).
To provide clinicians with a comprehensive set of data,
henever deemed appropriate or when published, the abso-
te risk difference and number needed to treat or harm will
provided in the guideline, along with the confidence
terval (CI) and data related to the relative treatment effects
ch as odds ratio (OR), relative risk (RR), hazard ratio (HR),
incidence rate ratio.
Consult the full-text version of the 2007 ACC/AHA
uidelines for the Management of Patients With Unstable
ngina/Non–ST-Elevation Myocardial Infarction (2) for pol-
y on clinical areas not covered by the focused update.
dividual recommendations updated in this focused update
ill be incorporated into future revisions and/or updates of
e full-text guidelines.
.2. Organization of Committee
or this focused update, all eligible members of the 2007
A/NSTEMI writing committee were invited to participate;
ose who agreed (referred to as the 2011 focused update
riting group) were required to disclose all RWI relevant to ble data under consideration. The committee comprised
presentatives from ACCF, AHA, American Academy of
amily Physicians, American College of Emergency Physi-
ans, American College of Physicians, Society for Cardio-
scular Angiography and Interventions, and Society of
horacic Surgeons.
.3. Document Review and Approval
his document was reviewed by 2 official reviewers each
minated by the ACCF and the AHA, as well as 1 or 2
viewers each from the American Academy of Family
hysicians, American College of Emergency Physicians,
merican College of Physicians, Society for Coronary An-
ography and Interventions, and Society of Thoracic Sur-
ons, and 25 individual content reviewers, including mem-
rs of the ACCF Interventional Scientific Council and
CCF Surgeon’s Scientific Council. The information on
viewers’ RWI was distributed to the writing group and is
blished in this document (Appendix 2).
This document was approved for publication by the gov-
ning bodies of the ACCF and the AHA and endorsed by
merican College of Emergency Physicians, Society for
ardiovascular Angiography and Interventions, and Society
Thoracic Surgeons.
. Early Hospital Care
.2. Recommendations for
ntiplatelet/Anticoagulant Therapy in
atients for Whom Diagnosis of UA/NSTEMI
Likely or Definite
.2.1. Recommendations for Antiplatelet Therapy
ee Table 2, and Appendixes 3, 4, 5, 6, 7, and 8 for
pplemental information.)
.2.3. Recommendations for Additional Management
f Antiplatelet and Anticoagulant Therapy
ee Table 3, and Appendixes 3, 4, 5, 6, 7, and 8 for
pplemental information.)
.2.3.1. ANTIPLATELET/ANTICOAGULANT THERAPY IN
TIENTS FOR WHOM DIAGNOSIS OF UA/NSTEMI IS LIKELY
R DEFINITE
.2.3.1.1. Thienopyridines. Thienopyridine therapy is an
portant component of antiplatelet therapy in patients with
A/NSTEMI and has been tested in several large trial
pulations with UA/NSTEMI. The last version of the
idelines recommended the use of clopidogrel in patients
ith UA/NSTEMI because it was the only US Food and Drug
dministration (FDA)–approved thienopyridine agent at that
me. Since the publication of the last guidelines (2), the FDA
s approved a second thienopyridine agent for use in
tients with UA/NSTEMI. The FDA approved the use of
asugrel based on data from a head-to-head comparison with
opidogrel, in which prasugrel was superior in reductions in
inical events but at the expense of an increased risk of
eeding.
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May 10, 2011:1920–59 UA/NSTEMI Guideline Focused UpdateThe pivotal trial (22) for prasugrel, TRITON-TIMI 38
rial to Assess Improvement in Therapeutic Outcomes by
ptimizing Platelet Inhibition with Prasugrel-Thrombolysis
Myocardial Infarction), focused on patients with acute
ronary syndrome (ACS) who were referred for percutane-
s coronary intervention (PCI). TRITON-TIMI 38 randomly
signed 13,608 patients with moderate- to high-risk ACS, of
hom 10,074 (74%) had UA/NSTEMI, to receive prasugrel
60-mg loading dose and a 10-mg daily maintenance dose)
clopidogrel (a 300-mg loading dose and a 75-mg daily
aintenance dose) for a median follow-up of 14.5 months.
cetylsalicylic acid (ASA) was prescribed within 24 hours of
CI. Clinical endpoints were assessed at 30 and 90 days and
en at 3-month intervals for 6 to 15 months. Among patients
ith UA/NSTEMI undergoing PCI, a prasugrel loading dose
as administered before, during, or within 1 hour after PCI
t only after coronary anatomy had been defined.
Prasugrel was associated with a significant 2.2% absolute
duction and a 19% relative reduction in the primary efficacy
dpoint, a composite of the rate of death due to cardiovas-
lar causes (including arrhythmia, congestive heart failure,
ock, and sudden or unwitnessed death), nonfatal myocar-
al infarction (MI), or nonfatal stroke during the follow-up
riod. The primary efficacy endpoint occurred in 9.9% of
tients receiving prasugrel and 12.1% of patients receiving
opidogrel (HR for prasugrel versus clopidogrel: 0.81; 95%
I: 0.73 to 0.90; p0.001) (22). Prasugrel decreased cardio-
scular death, MI, and stroke by 138 events (number needed
treat46). The difference in the primary endpoint was
rgely related to the difference in rates of nonfatal MI (7.3%
r prasugrel versus 9.5% for clopidogrel; HR: 0.76; 95% CI:
67 to 0.85; p0.001). Rates of cardiovascular death (2.1%
rsus 2.4%; p0.31) and nonfatal stroke (1.0% versus 1.0%;
0.93) were not reduced by prasugrel relative to clopi-
grel. Rates of stent thrombosis were significantly reduced
om 2.4% to 1.1% (p0.001) by prasugrel.
Prasugrel was associated with a significant increase in the
te of bleeding, notably TIMI (Thrombolysis In Myocardial
farction) major hemorrhage, which was observed in 2.4%
patients taking prasugrel and in 1.8% of patients taking
opidogrel (HR for prasugrel versus clopidogrel: 1.32; 95%
I: 1.03 to 1.68; p0.03). The increased RR of major
eeding was 32%. Prasugrel was associated with a signifi-
nt increase in fatal bleeding (0.4%) compared with clopi-
grel (0.1%) (p0.002). From the standpoint of safety,
asugrel was associated with an increase of 35 TIMI major
d non–coronary artery graft bypass (CABG) bleeds (num-
r needed to harm167) (22). Also, greater rates of life-
reatening bleeding were evident in the prasugrel group than
the clopidogrel group: 1.4% versus 0.9%, respectively (HR
r prasugrel: 1.52; 95% CI: 1.08 to 2.13; p0.01). In the few
tients who underwent CABG, TIMI major bleeding
rough 15 months was also greater with prasugrel than with
opidogrel (13.4% versus 3.2%, respectively; HR for prasu-
el: 4.73; 95% CI: 1.90 to 11.82; p0.001) (22). The net
inical benefit in the TRITON-TIMI 38 study demonstrated
primary efficacy and safety endpoint rate of 13.9% in the
opidogrel group versus 12.2% in the prasugrel group (HR:
87; 95% CI: 0.79 to 0.95; p0.004). suA post hoc analysis suggested there were 3 subgroups of
CS patients who did not have a favorable net clinical benefit
efined as the rate of death due to any cause, nonfatal MI,
nfatal stroke, or non–CABG-related nonfatal TIMI major
eeding) from the use of prasugrel or who had net harm:
atients with a history of stroke or transient ischemic attack
fore enrollment had net harm from prasugrel (HR: 1.54;
% CI: 1.02 to 2.32; p0.04); patients75 years of age had
net benefit from prasugrel (HR: 0.99; 95% CI: 0.81 to
21; p0.92); and patients with a body weight of 60 kg
d no net benefit from prasugrel (HR: 1.03; 95% CI: 0.69 to
53; p0.89). In both treatment groups, patients with at least
of these risk factors had higher rates of bleeding than those
ithout them (22).
The FDA cited a contraindication against use of prasugrel
patients with a history of transient ischemic attack or stroke
with active pathological bleeding (35). The FDA labeling
formation includes a general warning against the use of
asugrel in patients75 years of age because of concerns of
increased risk of fatal and intracranial bleeding and
certain benefit except in high-risk situations (patients with
abetes or a history of prior MI), in which case the net
nefit appears to be greater and its use may be considered
5). In focusing specifically on patients with UA/NSTEMI,
e rate of the primary efficacy endpoint was significantly
duced in favor of prasugrel (9.9% versus 12.1%; adjusted
R: 0.82; 95% CI: 0.73 to 0.93; p0.002) (22).
The writing group cautions that data on the use of prasugrel
me solely from the TRITON-TIMI 38 trial, and its use in
inical practice should carefully follow how it was tested in
at study (22). Prasugrel was administered only after a
cision to proceed to PCI was made. It is not our recom-
endation that prasugrel be administered routinely before
giography, such as in an emergency department, or be used
patients who have not undergone PCI. The FDA package
bel suggests that it is reasonable to consider selective use of
asugrel before catheterization in subgroups of patients for
hom a decision to proceed to angiography and PCI has
ready been established for any reason (35). The writing
oup acknowledges this flexibility, but it is not our intention
make specific recommendations about which subgroups of
tients might benefit from prasugrel instead of clopidogrel.
e do wish to caution clinicians about the potential bleeding
sks from prasugrel compared with clopidogrel, especially
ong the subgroups identified in the package insert (22,35).
.2.3.1.2. Choice of Thienopyridine for PCI in UA/
STEMI. These guidelines do not explicitly endorse one
the thienopyridines over the other. There were several
asons for this decision. Although the composite efficacy
dpoint favored prasugrel, driven predominantly by a dif-
rence in nonfatal MIs, with deaths and nonfatal strokes
ing similar, bleeding was increased in the prasugrel group
2). In addition, the comparison of the 2 drugs is based on a
ngle large trial. Also, the loading dose of clopidogrel in
RITON-TIMI 38 was lower than is currently recommended
these guidelines (22). Furthermore, some emerging studies
ggest there may be some patients who are resistant to
Ta
Cla
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2007 Recommendations 2011 Focused Update Recommendations Comments
ss I
ASA should be administered to UA/NSTEMI patients as soon as
possible after hospital presentation and continued indefinitely in
patients not known to be intolerant of that medication. (Level of
Evidence: A) (Figs. 7 and 8; Box A)
1. ASA* should be administered to UA/NSTEMI patients as soon as possible after
hospital presentation and continued indefinitely in patients who tolerate it (3–10).
(Level of Evidence: A)
Modified recommendation
(changed wording for
clarity).
Clopidogrel (loading dose followed by daily maintenance dose)
should be administered to UA/NSTEMI patients who are unable
to take ASA because of hypersensitivity or major gastrointestinal
intolerance. (Level of Evidence: A) (Figs. 7 and 8; Box A)
2. Clopidogrel (loading dose followed by daily maintenance dose) should be administered
to UA/NSTEMI patients who are unable to take ASA because of hypersensitivity or
major gastrointestinal intolerance (11–13). (Level of Evidence: B)
Modified recommendation
(level of evidence changed
from A to B because trials
do not address the
specific subgroups in this
recommendation).
In UA/NSTEMI patients with a history of gastrointestinal bleeding,
when ASA and clopidogrel are administered alone or in
combination, drugs to minimize the risk of recurrent
gastrointestinal bleeding (e.g., PPI), should be prescribed
concomitantly. (Level of Evidence: B)
Deleted recommendation
(see ACCF/ACG/AHA PPI
expert consensus
document [14]).
For UA/NSTEMI patients in whom an initial invasive strategy is
selected, antiplatelet therapy in addition to ASA should be
initiated before diagnostic angiography (upstream) with either
clopidogrel (loading dose followed by daily maintenance dose) or
an IV GP IIb/IIIa inhibitor. (Level of Evidence: A) Abciximab as
the choice for upstream GP IIb/IIIa therapy is indicated only if
there is no appreciable delay to angiography and PCI is likely to
be performed; otherwise, IV eptifibatide or tirofiban is the
preferred choice of GP IIb/IIIa inhibitor. (Level of Evidence: B)
3. Patients with definite UA/NSTEMI at medium or high risk and in whom an initial
invasive strategy is selected should receive dual-antiplatelet therapy on presentation
(13,15–17). (Level of Evidence: A) ASA should be initiated on presentation (3–8,10).
(Level of Evidence: A) The choice of a second antiplatelet therapy to be added to ASA
on presentation includes 1 of the following:
Before PCI:
● Clopidogrel (13,17) (Level of Evidence: B); or
● An IV GP IIb/IIIa inhibitor (18–21). (Level of Evidence: A) IV eptifibatide or tirofiban are
the preferred GP IIb/IIIa inhibitors.
At the time of PCI:
● Clopidogrel if not started before PCI (13,17) (Level of Evidence: A); or
● Prasugrel† (22) (Level of Evidence: B); or
● An IV GP IIb/IIIa inhibitor (18,21,23,24). (Level of Evidence: A)
Modified recommendation
(modified to include
prasugrel and define
therapy more clearly).
For UA/NSTEMI patients in whom an initial conservative (i.e.,
noninvasive) strategy is selected (see Section 3.3), clopidogrel
(loading dose followed by daily maintenance dose) should be
added to ASA and anticoagulant therapy as soon as possible
after admission and administered for at least 1 month (Level of
Evidence: A) and ideally up to 1 year. (Level of Evidence: B)
(Fig. 8; Box C2)
4. For UA/NSTEMI patients in whom an initial conservative (i.e., noninvasive) strategy is
selected (see Section 3.3), clopidogrel (loading dose followed by daily maintenance
dose) should be added to ASA and anticoagulant therapy as soon as possible after
admission and administered for at least 1 month (13) and ideally up to 1 year
(11,13). (Level of Evidence: B)
Modified recommendation
(changed level of evidence
from A to B for 1-month
clopidogrel administration).
For UA/NSTEMI patients in whom an initial conservative strategy
is selected, if recurrent symptoms/ischemia, HF or serious
arrhythmias subsequently appear, then diagnostic angiography
should be performed. (Level of Evidence: A) (Fig. 8; Box D)
Either an IV GP IIb/IIIa inhibitor (eptifibatide or tirofiban; Level of
Evidence: A) or clopidogrel (loading dose followed by daily
maintenance dose; Level of Evidence: A) should be added to
ASA and anticoagulant therapy before diagnostic angiography
(upstream). (Level of Evidence: C)
5. For UA/NSTEMI patients in whom an initial conservative strategy is selected, if
recurrent symptoms/ischemia, HF, or serious arrhythmias subsequently appear, then
diagnostic angiography should be performed (13,25,26). (Level of Evidence: A). Either
an IV GP IIb/IIIa inhibitor (eptifibatide or tirofiban (19–21) [Level of Evidence: A]) or
clopidogrel (loading dose followed by daily maintenance dose (13,15) [Level of
Evidence: B]) should be added to ASA and anticoagulant therapy before diagnostic
angiography (upstream). (Level of Evidence: C)
Modified recommendation
(changed level of evidence
from A to B for clopidogrel
addition).
6. A loading dose of thienopyridine is recommended for UA/NSTEMI patients for
whom PCI is planned. Regimens should be 1 of the following:
a. Clopidogrel 300 to 600 mg should be given as early as possible before or at
the time of PCI (13,27–31) (Level of Evidence: A) or
b. Prasugrel† 60 mg should be given promptly and no later than 1 hour after
PCI once coronary anatomy is defined and a decision is made to proceed
with PCI (22). (Level of Evidence: B)
New recommendation
(included to be concordant
with 2009 STEMI and PCI
Focused Update (32),
modified for the
UA/NSTEMI patient group).
7. The duration and maintenance dose of thienopyridine therapy should be as
follows:
a. In UA/NSTEMI patients undergoing PCI, clopidogrel 75 mg daily (17) or
prasugrel† 10 mg daily (22) should be given for at least 12 months (13,17).
(Level of Evidence: B)
b. If the risk of morbidity because of bleeding outweighs the anticipated
benefits afforded by thienopyridine therapy, earlier discontinuation should be
considered. (Level of Evidence: C)
New recommendation
(included to be concordant
with 2009 STEMI and PCI
Focused Update [32]).
(Continued)
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May 10, 2011:1920–59 UA/NSTEMI Guideline Focused Updateopidogrel, but there is little information about the use of
rategies to select patients who might do better with prasu-
el. Considerations of efficacy in the prevention of throm-
sis and risk of an adverse effect related to bleeding and
perience with a given medication may best guide decisions
out the choice of thienopyridine for individual patients
6).
There may be other options for oral antiplatelet efficacy in
e not too distant future. Ticagrelor is a reversible nonthien-
ble 2. Continued
2007 Recommendations
ss IIa
For UA/NSTEMI patients in whom an initial conservative strategy
is selected and who have recurrent ischemic discomfort with
clopidogrel, ASA, and anticoagulant therapy, it is reasonable to
add a GP IIb/IIIa antagonist before diagnostic angiography. (Level
of Evidence: C)
1. For UA/NSTEMI pat
have recurrent isch
it is reasonable to
Evidence: C)
For UA/NSTEMI patients in whom an initial invasive strategy is
selected, it is reasonable to omit upstream administration of an
IV GP IIb/IIIa antagonist before diagnostic angiography if
bivalirudin is selected as the anticoagulant and at least 300 mg
of clopidogrel was administered at least 6 hours earlier than
planned catheterization or PCI. (Level of Evidence: B)
2. For UA/NSTEMI pat
reasonable to omit
as the anticoagulan
hours earlier than
ss IIb
For UA/NSTEMI patients in whom an initial conservative (i.e.,
noninvasive) strategy is selected, it may be reasonable to add
eptifibatide or tirofiban to anticoagulant and oral antiplatelet
therapy. (Level of Evidence: B) (Fig. 8; Box C2)
1. For UA/NSTEMI pat
selected, it may be
oral antiplatelet the
2. Prasugrel† 60 mg
in patients with UA
anatomy if both the
unlikely (22,35,36).
3. The use of upstrea
patients already re
strategy, such as t
segment depressio
(19,20,25,27,37). (
4. In patients with de
strategy, the use o
maintenance dose
in patients not con
ss III: No Benefit
Abciximab should not be administered to patients in whom PCI
is not planned. (Level of Evidence: A)
1. Abciximab should n
(Level of Evidence:
2. In UA/NSTEMI patie
2) or at high risk
upstream GP IIb/
Evidence: B)
ss III: Harm
1. In UA/NSTEMI patie
planned, prasugrel
(22). (Level of Evid
*Refer to the ACC/AHA/SCAI Guideline for Percutaneous Coronary Intervention
†Patients weighing60 kg have an increased exposure to the active metaboli
se. Consideration should be given to lowering the maintenance dose to 5 mg
se have not been studied prospectively. For post-PCI patients receiving a BM
to 15 months unless the risk of bleeding outweighs the anticipated net benefit
eeding or a history of TIA or stroke. In patients 75 years of age, prasugrel i
eeding and uncertain benefit except in high-risk situations (patients with diabe
considered. Do not start prasugrel in patients likely to undergo urgent CABG. W
k factors for bleeding include body weight 60 kg, propensity to bleed, and
parin, fibrinolytic therapy, or chronic use of nonsteroidal anti-inflammatory dyridine P2Y12 receptor antagonist that has been tested in a Nad-to-head comparison with clopidogrel in PLATO (Study
Platelet Inhibition and Patient Outcomes) (87). It is not a
odrug like clopidogrel and prasugrel and thus does not
quire bioactivation (87,88). Ticagrelor reduced the risks of
ath and MI but at the expense of an increase in nonproce-
ral bleeding (87). Ticagrelor was not FDA approved or
arketed at the time of writing of this update; hence, we
uld not recommend it for use in patients with UA/NSTEMI,
though it may have a future role in patients with UA/
ocused Update Recommendations Comments
hom an initial conservative strategy is selected and who
omfort with clopidogrel, ASA, and anticoagulant therapy,
IIb/IIIa inhibitor before diagnostic angiography. (Level of
2007 recommendation
remains current.
hom an initial invasive strategy is selected, it is
ation of an IV GP IIb/IIIa inhibitor if bivalirudin is selected
least 300 mg of clopidogrel was administered at least 6
atheterization or PCI (16,33,34). (Level of Evidence: B)
Modified recommendation
(removed language about
diagnostic angiography).
hom an initial conservative (i.e., noninvasive) strategy is
le to add eptifibatide or tirofiban to anticoagulant and
20). (Level of Evidence: B)
2007 recommendation
remains current.
onsidered for administration promptly upon presentation
for whom PCI is planned, before definition of coronary
bleeding is low and the need for CABG is considered
Evidence: C)
New recommendation
IIIa inhibitors may be considered in high-risk UA/NSTEMI
A and a thienopyridine who are selected for an invasive
elevated troponin levels, diabetes, or significant ST-
o are not otherwise at high risk for bleeding
vidence: B)
New recommendation
STEMI undergoing PCI as part of an early invasive
g dose of clopidogrel of 600 mg, followed by a higher
g daily for 6 days, then 75 mg daily may be reasonable
high risk for bleeding (28). (Level of Evidence: B)
New recommendation
ministered to patients in whom PCI is not planned (21,23). 2007 recommendation
remains current.
are at low risk for ischemic events (e.g., TIMI risk score
ing and who are already receiving ASA and clopidogrel,
tors are not recommended (25,36–38). (Level of
New recommendation
a prior history of stroke and/or TIA for whom PCI is
ally harmful as part of a dual-antiplatelet therapy regimen
New recommendation
(included to be concordant
with 2009 STEMI and PCI
Focused Update [32]).
g-term dosing of ASA following stent placement.
sugrel and an increased risk of bleeding on a 10-mg once–daily maintenance
nts who weigh 60 kg, although the effectiveness and safety of the 5-mg
, a daily maintenance dose should be given for at least 12 months and for
by a thienopyridine. Do not use prasugrel in patients with active pathological
lly not recommended because of the increased risk of fatal and intracranial
history of prior MI), in which its effect appears to be greater and its use may
sible, discontinue prasugrel at least 7 days before any surgery (35). Additional
itant use of medications that increase the risk of bleeding (e.g., warfarin,
).2011 F
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2007 Recommendations 2011 Focused Update Recommendations Comments
ss I
For UA/NSTEMI patients in whom an initial conservative strategy is selected
and no subsequent features appear that would necessitate diagnostic
angiography (recurrent symptoms/ischemia, HF, or serious arrhythmias), a
stress test should be performed. (Level of Evidence: B) (Fig. 8; Box O)
If, after stress testing, the patient is classified as not at low risk,
diagnostic angiography should be performed. (Level of Evidence: A) (Fig.
8; Box E1)
If, after stress testing, the patient is classified as being at low risk (Fig.
8; Box E2), the instructions noted below should be followed in
preparation for discharge (Fig. 8; Box K) (Level of Evidence: A):
1. Continue ASA indefinitely. (Level of Evidence: A)
2. Continue clopidogrel for at least 1 month (Level of Evidence: A) and
ideally up to 1 year. (Level of Evidence: B)
3. Discontinue IV GP IIb/IIIa inhibitor if started previously. (Level of
Evidence: A)
4. Continue UFH for 48 hours or administer enoxaparin or fondaparinux
for the duration of hospitalization, up to 8 days, and then discontinue
anticoagulant therapy. (Level of Evidence: A)
1. For UA/NSTEMI patients in whom an initial conservative strategy is selected
and no subsequent features appear that would necessitate diagnostic
angiography (recurrent symptoms/ischemia, HF, or serious arrhythmias), a
stress test should be performed (26). (Level of Evidence: B)
a. If, after stress testing, the patient is classified as not at low risk,
diagnostic angiography should be performed (25,26). (Level of
Evidence: A)
b. If, after stress testing, the patient is classified as being at low risk, the
instructions noted below should be followed in preparation for discharge
(25,26):
1. Continue ASA indefinitely (4,6,10). (Level of Evidence: A)
2. Continue clopidogrel for at least 1 month (13) and ideally up to 1
year (11,13). (Level of Evidence: B)
3. Discontinue IV GP IIb/IIIa inhibitor if started previously (19,20). (Level
of Evidence: A)
4. Continue UFH for 48 hours (8,39) (Level of Evidence: A) or administer
enoxaparin (40–42) (Level of Evidence: A) or fondaparinux (43) (Level
of Evidence: B) for the duration of hospitalization, up to 8 days, and
then discontinue anticoagulant therapy.
Modified recommendation
(changed level of evidence
from A to B for 1-month
clopidogrel administration;
clarified levels of evidence
for UFH, enoxaparin, and
fondaparinux).
For UA/NSTEMI patients in whom CABG is selected as a postangiography
management strategy, the instructions noted below should be followed (Fig. 9;
Box G).
Continue ASA. (Level of Evidence: A)
Discontinue clopidogrel 5 to 7 days before elective CABG. (Level of
Evidence: B) More urgent surgery, if necessary, may be performed by
experienced surgeons if the incremental bleeding risk is considered
acceptable. (Level of Evidence: C)
Discontinue IV GP IIb/IIIa inhibitor (eptifibatide or tirofiban) 4 hours before
CABG. (Level of Evidence: B)
Anticoagulant therapy should be managed as follows:
1. Continue UFH. (Level of Evidence: B)
2. Discontinue enoxaparin* 12 to 24 hours before CABG and dose with
UFH per institutional practice. (Level of Evidence: B)
3. Discontinue fondaparinux 24 hours before CABG and dose with UFH
per institutional practice. (Level of Evidence: B)
4. Discontinue bivalirudin 3 hours before CABG and dose with UFH per
institutional practice. (Level of Evidence: B)
2. For UA/NSTEMI patients in whom CABG is selected as a postangiography
management strategy, the instructions noted below should be followed.
a. Continue ASA (44–48). (Level of Evidence: A)
b. See Class I, #3, in this section.
c. Discontinue IV GP IIb/IIIa inhibitor (eptifibatide or tirofiban) 4 hours before
CABG (49–51). (Level of Evidence: B)
d. Anticoagulant therapy should be managed as follows:
1. Continue UFH (40,52–54). (Level of Evidence: B)
2. Discontinue enoxaparin 12 to 24 hours before CABG and dose with
UFH per institutional practice (40,52–54). (Level of Evidence: B)
3. Discontinue fondaparinux 24 hours before CABG and dose with UFH
per institutional practice (55,56). (Level of Evidence: B)
4. Discontinue bivalirudin 3 hours before CABG and dose with UFH per
institutional practice (57,58). (Level of Evidence: B)
Modified recommendation
(changed item “b” to
include prasugrel and be a
stand-alone
recommendation; see
Class I, #3, in this
section).
For UA/NSTEMI patients in whom CABG is selected as a postangiography
management strategy, the instructions noted below should be followed (Fig. 9;
Box G).
Discontinue clopidogrel 5 to 7 days before elective CABG. (Level of
Evidence: B) More urgent surgery, if necessary, may be performed by
experienced surgeons if the incremental bleeding risk is considered
acceptable. (Level of Evidence: C)
3. In patients taking a thienopyridine in whom CABG is planned and can be delayed,
it is recommended that the drug be discontinued to allow for dissipation of the
antiplatelet effect (13) (Level of Evidence: B) The period of withdrawal should be
at least 5 days in patients receiving clopidogrel (13,18,59) (Level of Evidence: B)
and at least 7 days in patients receiving prasugrel* (35) (Level of Evidence: C)
unless the need for revascularization and/or the net benefit of the thienopyridine
outweighs the potential risks of excess bleeding (60). (Level of Evidence: C)
Modified recommendation
(changed to include
prasugrel and update
length of withdrawal
period; from Class I, #2, in
this section).
For UA/NSTEMI patients in whom PCI has been selected as a postangiography
management strategy, the instructions noted below should be followed (Fig. 9;
Box H):
Continue ASA. (Level of Evidence: A)
Administer a loading dose of clopidogrel if not started before diagnostic
angiography. (Level of Evidence: A)
Administer an IV GP IIb/IIIa inhibitor (abciximab, eptifibatide, or tirofiban) if
not started before diagnostic angiography for troponin-positive and other
high-risk patients (Level of Evidence: A). See Class IIa recommendation
below if bivalirudin was selected as the anticoagulant.
Discontinue anticoagulant therapy after PCI for uncomplicated cases.
(Level of Evidence: B)
4. For UA/NSTEMI patients in whom PCI has been selected as a
postangiography management strategy, the instructions noted below should
be followed:
a. Continue ASA (4,6,10). (Level of Evidence: A)
b. Administer a loading dose of a thienopyridine if not started before
diagnostic angiography (12,29,31,61,62). (Level of Evidence: A)
c. See Class IIa, #1, in this section.
d. Discontinue anticoagulant therapy after PCI for uncomplicated cases
(40,41,63–65). (Level of Evidence: B)
Modified recommendation
(included language to
allow for prasugrel as
choice of thienopyridine;
class of item “c” changed
from I to IIa).
For UA/NSTEMI patients in whom medical therapy is selected as a
management strategy and in whom no significant obstructive CAD on
angiography was found, antiplatelet and anticoagulant therapy should be
administered at the discretion of the clinician (Level of Evidence: C). For
patients in whom evidence of coronary atherosclerosis is present (e.g., luminal
irregularities or intravascular ultrasound-demonstrated lesions), albeit without
flow-limiting stenoses, long-term treatment with ASA and other secondary
prevention measures should be prescribed. (Fig. 9; Box I) (Level of Evidence: C)
5. For UA/NSTEMI patients in whom medical therapy is selected as a management
strategy and in whom no significant obstructive CAD on angiography was found,
antiplatelet and anticoagulant therapy should be administered at the discretion of
the clinician (Level of Evidence: C). For patients in whom evidence of coronary
atherosclerosis is present (e.g., luminal irregularities or intravascular ultrasound-
demonstrated lesions), albeit without flow-limiting stenoses, long-term treatment
with ASA and other secondary prevention measures should be prescribed. (Level
of Evidence: C)
2007 recommendation
remains current.
(Continued)
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2007 Recommendations 2011 Focused Update Recommendations Comments
For UA/NSTEMI patients in whom medical therapy is selected as a management
strategy and in whom CAD was found on angiography, the following approach is
recommended (Fig. 9; Box J):
Continue ASA. (Level of Evidence: A)
Administer a loading dose of clopidogrel if not given before diagnostic
angiography. (Level of Evidence: A)
Discontinue IV GP IIb/IIIa inhibitor if started previously. (Level of Evidence: B)
Anticoagulant therapy should be managed as follows:
1. Continue IV UFH for at least 48 hours or until discharge if given before
diagnostic angiography. (Level of Evidence: A)
2. Continue enoxaparin for duration of hospitalization, up to 8 days, if given
before diagnostic angiography. (Level of Evidence: A)
3. Continue fondaparinux for duration of hospitalization, up to 8 days, if
given before diagnostic angiography. (Level of Evidence: B)
4. Either discontinue bivalirudin or continue at a dose of 0.25 mg/kg per
hour for up to 72 hours at the physician’s discretion, if given before
diagnostic angiography. (Level of Evidence: B)
6. For UA/NSTEMI patients in whom medical therapy is selected as a
management strategy and in whom CAD was found on angiography, the
following approach is recommended:
a. Continue ASA (4,6,10). (Level of Evidence: A)
b. Administer a loading dose of clopidogrel if not given before diagnostic
angiography (13). (Level of Evidence: B)
c. Discontinue IV GP IIb/IIIa inhibitor if started previously (16,19,20,38).
(Level of Evidence: B)
d. Anticoagulant therapy should be managed as follows:
1. Continue IV UFH for at least 48 hours or until discharge if given
before diagnostic angiography (8,39,40). (Level of Evidence: A)
2. Continue enoxaparin for duration of hospitalization, up to 8 days, if
given before diagnostic angiography (40–42,56). (Level of Evidence: A)
3. Continue fondaparinux for duration of hospitalization, up to 8 days, if
given before diagnostic angiography (43). (Level of Evidence: B)
4. Either discontinue bivalirudin or continue at a dose of 0.25 mg/kg
per hour for up to 72 hours at the physician’s discretion if given
before diagnostic angiography (34,67,68). (Level of Evidence: B)
Modified recommendation
(changed level of evidence
from A to B for clopidogrel
loading dose).
For UA/NSTEMI patients in whom a conservative strategy is selected and who do
not undergo angiography or stress testing, the instructions noted below should
be followed (Fig. 8; Box K):
Continue ASA indefinitely. (Level of Evidence: A)
Continue clopidogrel for at least 1 month (Level of Evidence: A) and ideally
up to 1 year. (Level of Evidence: B)
Discontinue IV GP IIb/IIIa inhibitor if started previously. (Level of Evidence: A)
Continue UFH for 48 hours or administer enoxaparin or fondaparinux for the
duration of hospitalization, up to 8 days, and then discontinue anticoagulant
therapy. (Level of Evidence: A)
7. For UA/NSTEMI patients in whom a conservative strategy is selected and
who do not undergo angiography or stress testing, the instructions noted
below should be followed:
a. Continue ASA indefinitely (4,6,10). (Level of Evidence: A)
b. Continue clopidogrel for at least 1 month (13) and ideally up to 1 year
(11,13,121). (Level of Evidence: B)
c. Discontinue IV GP IIb/IIIa inhibitor if started previously (19,20). (Level of
Evidence: A)
d. Continue UFH for 48 hours (8,39) (Level of Evidence: A) or administer
enoxaparin (40–42) (Level of Evidence: A) or fondaparinux (Level of
Evidence: B) for the duration of hospitalization, up to 8 days (43), and
then discontinue anticoagulant therapy.
Modified recommendation
(changed level of evidence
from A to B for 1-month
clopidogrel administration).
For UA/NSTEMI patients in whom an initial conservative strategy is selected and
in whom no subsequent features appear that would necessitate diagnostic
angiography (recurrent symptoms/ischemia, HF, or serious arrhythmias), LVEF
should be measured. (Level of Evidence: B) (Fig. 8; Box L)
8. For UA/NSTEMI patients in whom an initial conservative strategy is selected and
in whom no subsequent features appear that would necessitate diagnostic
angiography (recurrent symptoms/ischemia, HF, or serious arrhythmias), LVEF
should be measured (25,69–72). (Level of Evidence: B)
2007 recommendation
remains current.
ss IIa
1. For UA/NSTEMI patients in whom PCI has been selected as a postangiography
management strategy, it is reasonable to administer an IV GP IIb/IIIa inhibitor
(abciximab, eptifibatide, or tirofiban) if not started before diagnostic angiography,
particularly for troponin-positive and/or other high-risk patients (25,27). (Level of
Evidence: A)
Modified recommendation
(see Class I, #4, in this
section).
For UA/NSTEMI patients in whom PCI is selected as a management strategy, it is
reasonable to omit administration of an IV GP IIb/IIIa antagonist if bivalirudin was
selected as the anticoagulant and at least 300 mg of clopidogrel was
administered at least 6 hours earlier. (Level of Evidence: B) (Fig. 9)
2. For UA/NSTEMI patients in whom PCI is selected as a management strategy, it is
reasonable to omit administration of an IV GP IIb/IIIa inhibitor if bivalirudin was
selected as the anticoagulant and at least 300 mg of clopidogrel was
administered at least 6 hours earlier (16,25). (Level of Evidence: B)
2007 recommendation
remains current.
If LVEF is 0.40, it is reasonable to perform diagnostic angiography. (Level of
Evidence: B) (Fig. 8; Box M)
3. If LVEF is 0.40, it is reasonable to perform diagnostic angiography (69–72).
(Level of Evidence: B)
2007 recommendation
remains current.
If LVEF is greater than 0.40, it is reasonable to perform a stress test. (Level of
Evidence: B) (Fig. 8; Box N)
4. If LVEF is greater than 0.40, it is reasonable to perform a stress test (69). (Level
of Evidence: B)
2007 recommendation
remains current.
ss IIb
For UA/NSTEMI patients in whom PCI is selected as a management strategy, it
may be reasonable to omit an IV GP IIb/IIIa inhibitor if not started before
diagnostic angiography for troponin-negative patients without other clinical or
angiographic high-risk features. (Level of Evidence: C)
Deleted recommendation
1. Platelet function testing to determine platelet inhibitory response in patients with
UA/NSTEMI (or, after ACS and PCI) on thienopyridine therapy may be considered
if results of testing may alter management (73–77). (Level of Evidence: B)
New recommendation
2. Genotyping for a CYP2C19 loss of function variant in patients with UA/NSTEMI (or,
after ACS and with PCI) on clopidogrel therapy might be considered if results of
testing may alter management (78–84). (Level of Evidence: C)
New recommendation
ss III: No Benefit
IV fibrinolytic therapy is not indicated in patients without acute ST-segment
elevation, a true posterior MI, or a presumed new left bundle-branch block.
(Level of Evidence: A)
1. IV fibrinolytic therapy is not indicated in patients without acute ST-segment
elevation, a true posterior MI, or a presumed new left bundle-branch block (85).
(Level of Evidence: A)
2007 recommendation
remains current.
*Patients weighing 60 kg have an increased exposure to the active metabolite of prasugrel and an increased risk of bleeding on a 10-mg once–daily maintenance dose. Consideration should
given to lowering the maintenance dose to 5 mg in patients who weigh60 kg, although the effectiveness and safety of the 5-mg dose have not been studied prospectively. For post-PCI patients
eiving a bare-metal stent (BMS) or drug-eluting stent (DES), a daily maintenance dose should be given for at least 12 months and for up to 15 months unless the risk of bleeding outweighs the
ticipated net benefit afforded by a thienopyridine. Do not use prasugrel in patients with active pathological bleeding or a history of TIA or stroke. In patients75 years of age, prasugrel is generally
t recommended because of the increased risk of fatal and intracranial bleeding and uncertain benefit except in high-risk situations (patients with diabetes or a history of prior MI), in which its effect
pears to be greater and its use may be considered. Do not start prasugrel in patients likely to undergo urgent CABG. When possible, discontinue prasugrel at least 7 days before any surgery (35).
ditional risk factors for bleeding include body weight60 kg, propensity to bleed, and concomitant use of medications that increase the risk of bleeding (e.g., warfarin, heparin, fibrinolytic therapy,
chronic use of nonsteroidal anti-inflammatory drugs) (35).
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herapy for Surgical Procedures. The writing group
eighed the current data on the use of thienopyridine
erapy in patients who remain hospitalized after UA/
STEMI and are candidates for CABG and retained the
007 recommendation (2) of empirical discontinuation of
opidogrel therapy for at least 5 days (13) and advocated
period of at least 7 days in patients receiving prasugrel for
s discontinuation before planned CABG (35). Ulti-
ately, the patient’s clinical status will determine the
sk-to-benefit ratio of CABG compared with awaiting
storation of platelet function.
2.3.1.3. Interindividual Variability in Responsiveness
Clopidogrel. Although clopidogrel in combination with
SA has been shown to reduce recurrent coronary events in
e posthospitalized ACS population (13,17), the response to
opidogrel varies among patients, and diminished respon-
veness to clopidogrel has been observed (89,90). Clopi-
grel is a prodrug and requires conversion to R130964, its
tive metabolite, through a 2-step process in the liver that
volves several CYP450 isoenzymes (81); of these, the
YP2C19 isoenzyme is responsible for almost half of the first
ep formation (78). At least 3 major genetic polymorphisms
the CYP2C19 isoenzyme are associated with loss of
nction: CYP2C19*1, *2, and *3 (78–80). The CYP2C19*2
d *3 variants account for 85% and 99% of the loss-of-
nction alleles in Caucasians and Asians, respectively (78).
here are ethnic differences in the prevalence of these
ss-of-function alleles among Caucasians, African Ameri-
ns, Asians, and Latinos, but all of these groups have some
pression of them.
Data from a number of observational studies have demon-
rated an association between an increased risk of adverse
rdiovascular events and the presence of 1 of the nonfunc-
oning alleles (79,81,83,84,89–93) and are well delineated in
e ACCF/AHA Clopidogrel Clinical Alert (78).
Prasugrel, the second FDA-approved thienopyridine for
e in ACS, is also a prodrug that requires conversion to its
tive metabolite. Prasugrel requires a single CYP-dependent
ep for its oxidation to the active metabolite, and at least 2
servational studies have demonstrated no significant de-
ease in plasma concentrations or platelet inhibition activity
carriers of at least 1 loss-of-function allele of the CYP2C19
oenzyme (94,95).
Since the FDA announced a “Boxed Warning” on March
, 2010, about the diminished effectiveness of clopidogrel in
tients with an impaired ability to convert the drug into its
tive form (86), there has been much interest in whether
inicians should perform routine testing in patients being
eated with clopidogrel. The routine testing could be for
netic variants of the CYP2C19 allele and/or for overall
fectiveness for inhibition of platelet activity. The ACCF/
HA Clopidogrel Clinical Alert expertly summarizes the
sues surrounding clopidogrel and the use of genotype
sting, as well as the potential for routine platelet function
sting (78).
The FDA label revision does not mandate testing forYP2C19 genotypes or overall platelet function (86). The unvision serves to warn clinicians that certain patient sub-
oups may exhibit reduced clopidogrel-mediated platelet
hibition and emphasizes that clinicians should be aware of
ternative treatment strategies to tailor alternative therapies
hen appropriate.
A number of commercially available genetic test kits will
entify the presence of 1 of the loss-of-function CYP2C19
leles, but these tests are expensive and not routinely covered
most insurance policies. Additionally, there are no pro-
ective studies that demonstrate that the routine use of these
sts coupled with modification of antiplatelet therapy im-
oves clinical outcomes or reduces subsequent clinical
ents. At least 11 ongoing studies are examining whether
notype assessment with attendant alteration in antiplatelet
erapy for those with loss-of-function alleles can improve
inical outcomes. On the basis of the current evidence, it is
fficult to strongly recommend genotype testing routinely in
tients with ACS, but it might be considered on a case-by-
se basis, especially in patients who experience recurrent
CS events despite ongoing therapy with clopidogrel.
Some argue that clinicians should consider routine testing
platelet function, especially in patients undergoing high-
sk PCI (78), to maximize efficacy while maintaining safety.
gain, no completed prospective studies have examined such
approach to guide such a sweeping change in clinical
anagement. At least 4 randomized clinical evaluation stud-
s being conducted now are testing the hypothesis that
utine platelet function testing should be used to tailor
tiplatelet therapy, and any strong recommendation regard-
g more widespread use of such testing must await the
sults of these trials. The lack of evidence does not mean
ck of efficacy or potential benefit, but the prudent physician
ould maintain an open yet critical mind-set about the
ncept until data are available from 1 of the ongoing
ndomized clinical trials examining this strategy.
Our recommendations for the use of genotype testing and
atelet function testing seek to strike a balance between not
posing an undue burden on clinicians, insurers, and society
implement these strategies in patients with UA or NSTEMI
d that of acknowledging the importance of these issues to
tients with UA/NSTEMI. Our recommendations that the
e of either strategy may have some benefit should be taken
the context of the remarks in this update, as well as the
ore comprehensive analysis in the ACCF/AHA Clopidogrel
linical Alert (78). The Class IIb classification of these strategies
ggests that a selective, limited approach to platelet genotype
sessment and platelet function testing is the more prudent
urse until better clinical evidence exists for us to provide a
ore scientifically derived recommendation.
.2.3.1.4. Optimal Loading and Maintenance Dosages
f Clopidogrel. Some have suggested that the loading and
aintenance doses of clopidogrel should be altered to ac-
unt for potential reduced responsiveness to clopidogrel
erapy or that some subgroups of high-risk patients should
treated preferentially with prasugrel (78). Accordingly, the
timal loading and short-term maintenance dosing for clopi-
grel in patients with UA/NSTEMI undergoing PCI is
certain.
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May 10, 2011:1920–59 UA/NSTEMI Guideline Focused UpdateLoading and short-term maintenance doses of clopidogrel
ere studied in CURRENT-OASIS 7 (Clopidogrel optimal
ading dose Usage to Reduce Recurrent EveNTs–
rganization to Assess Strategies in Ischemic Syndromes),
ith published data demonstrating a potential benefit of
gher-dose clopidogrel in patients with definite UA/
STEMI undergoing an invasive management strategy
8,96). The CURRENT-OASIS trial randomized 25,086
tients with ACS who were intended for PCI and who were
t considered to be at high risk for bleeding to receive
gher-dose clopidogrel (600 mg loading, 150 mg daily for 6
ys, 75 mg daily thereafter) versus standard-dose clopi-
grel (300 mg loading, 75 mg daily) as part of a 22 design
at also compared maintenance higher-dose ASA (300 to
5 mg daily) with low-dose ASA (75 to 100 mg daily). All
tients received 300 mg of ASA on Day 1 regardless of
ndomization after Day 1. The primary endpoint of the trial
as the combination of cardiovascular death, myocardial
e)infarction, or stroke at 30 days. Although the overall trial
6) failed to demonstrate a significant difference in the
imary endpoint between the clopidogrel and ASA groups
.2% versus 4.4%), the PCI subset (n17,263) did show
gnificant differences in the clopidogrel arm (28). The
imary outcome was reduced in the PCI subgroup random-
ed to higher-dose clopidogrel (3.9% versus 4.5%;
0.035), and this was largely driven by a reduction in
yocardial (re)infarction (2.0% versus 2.6%; p0.017). Def-
ite stent thrombosis was reduced in the higher-dose clopi-
grel group (0.7% versus 1.3%; p0.0001), with consistent
sults across drug-eluting stent versus non–drug-eluting
ent subtypes. Higher-dose clopidogrel therapy increased
ajor bleeding in the entire group (2.5% versus 2.0%;
0.012) and the PCI subgroup (1.1% versus 0.7%;
0.008). The benefit of higher-dose clopidogrel loading
as offset by an increase in major bleeding (96).
As noted in the Dosing Table (Appendix 4), the current
commended loading dose for clopidogrel is uncertain. In
dition, several hours are required to metabolize clopidogrel
its active metabolite, leaving a window of time where there
a reduced level of effectiveness even in patients who
spond to clopidogrel.
.2.3.1.5. Proton Pump Inhibitors and Dual-
ntiplatelet Therapy for Acute Coronary Syndrome.
roton pump inhibitor (PPI) medications* have been found to
terfere with the metabolism of clopidogrel. When clopi-
grel is started, PPIs are often prescribed prophylactically to
event gastrointestinal complications such as ulceration and
lated bleeding (97) due to dual-antiplatelet therapy, in
rticular ASA and clopidogrel (90). Coupled with concern
out the gastrointestinal precautions, there has been in-
eased emphasis on the prevention of premature discontin-
tion of dual-antiplatelet therapy, particularly in patients
ho have received a drug-eluting stent for whom 12 months
antiplatelet therapy is recommended (98).
PIs include omeprazole, lansoprazole, pantoprazole, rabeprazole, and esomepra-
le (which are all available by prescription). Omeprazole is also sold over thedounter for frequent heartburn.There have been retrospective reports of adverse cardio-
scular outcomes (e.g., readmission for ACS) when the
tiplatelet regimen of clopidogrel and ASA is accompanied
PPIs assessed as a group compared with use of this
gimen without a PPI (90,99,101). In a retrospective cohort
udy from the Veterans Affairs’ medical records and phar-
acy database, concomitant clopidogrel and PPI therapy
ith omeprazole, rabeprazole, lansoprazole, or pantopra-
le) at any time during follow-up of 8205 patients dis-
arged for ACS was associated with an increased risk of
ath or rehospitalization for ACS (90). Other post hoc study
alyses (83,102) and a retrospective data analysis from the
ational Heart, Lung, and Blood Institute Dynamic Registry
03), in which PPIs were assessed as a class in combination
ith a clopidogrel and an ASA regimen, have not found an
fect of PPI therapy on the clinical effect of clopidogrel in
CS patients, post-ACS patients, and a general post-PCI
pulation, respectively (83,103).
Some studies have suggested that adverse cardiovascular
tcomes with the combination of clopidogrel and a PPI are
plained by the individual PPI, in particular, the use of a PPI
at inhibits CYP450 2C19, including omeprazole, lansopra-
le, or rabeprazole. Notably, the PPI omeprazole has been
ported to significantly decrease the inhibitory effect of
opidogrel on platelet aggregation (104,105). One study
ported that the PPI pantoprazole was not associated with
current MI among patients receiving clopidogrel, possibly
e to pantoprazole’s lack of inhibition of CYP450 2C19
9).
Other studies have examined the thienopyridine agent
escribed with the PPI. One open-label drug study evaluated
e effects of the PPI lansoprazole on the pharmacokinetics
d pharmacodynamics of prasugrel and clopidogrel in
althy subjects given single doses of prasugrel 60 mg and
opidogrel 300 mg with and without concurrent lansoprazole
mg per day. The data suggest that inhibition of platelet
gregation was reduced in patients who took the combina-
on of clopidogrel and lansoprazole, whereas platelet aggre-
tion was unaffected after a prasugrel dose (106).
Another study (101) assessed the association of PPIs with
e pharmacodynamics and clinical efficacy of clopidogrel
d prasugrel, based on populations from 2 randomized trials,
e PRINCIPLE (Prasugrel In Comparison to Clopidogrel for
hibition of Platelet Activation and Aggregation) TIMI-44
ial (107) and the TRITON-TIMI 38 trial (22). The findings
dicated that first, PPI treatment attenuated the pharmacody-
mic effects of clopidogrel and, to a lesser extent, those of
asugrel. Second, PPI treatment did not affect the clinical
tcome of patients given clopidogrel or prasugrel. This
nding was true for all PPIs that were studied, including
eprazole and pantoprazole.
Observational trials may be confounded by selection bias.
a preliminary report of a randomized study (the COGENT
lopidogrel and the Optimization of Gastrointestinal Events]
udy [108]; see Appendix 7), omeprazole was compared with
acebo in 3627 patients starting dual-antiplatelet therapy
ith ASA and clopidogrel. No difference was found in the
imary composite cardiovascular endpoint between clopi-
grel plus omeprazole and clopidogrel plus placebo (HR:
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UA/NSTEMI Guideline Focused Update May 10, 2011:1920–5902), but gastrointestinal bleeding complications were re-
ced (108). Clearly, more controlled, randomized clinical
ial data are needed to address the clinical impact of
njunctive therapy with clopidogrel and PPIs.
The FDA communication on an ongoing safety review of
opidogrel bisulfate (86) advises that healthcare providers
ould reevaluate the need for starting or continuing treat-
ent with a PPI, including omeprazole, in patients taking
opidogrel. The FDA notes there is no evidence that other
ugs that reduce stomach acid, such as H2 blockers or
tacids, interfere with the antiplatelet activity of clopidogrel.
ealthcare providers should continue to prescribe and pa-
ents should continue to take clopidogrel as directed, because
opidogrel has demonstrated benefits in preventing blood
ots that could lead to a heart attack or stroke. Healthcare
oviders should reevaluate the need for starting or continu-
g treatment with a PPI, including omeprazole (over the
unter), in patients taking clopidogrel. Patients taking clopi-
grel should consult their healthcare provider if they are
rrently taking or considering taking a PPI, including
eprazole (86). Most recently, the ACC has released a
atement on the use of PPI agents in combination with
opidogrel. The expert consensus statement does not prohibit
e use of PPI agents in appropriate clinical settings, yet
ghlights the potential risks and benefits from use of PPI
ents in combination with clopidogrel (14).
.2.3.1.6. Glycoprotein IIb/IIIa Receptor Antagonists.
he efficacy of glycoprotein (GP) IIb/IIIa inhibitor therapy
s been well established during PCI procedures and in
tients with UA/NSTEMI, particularly among high-risk
tients such as those with elevated troponin biomarkers,
ose with diabetes, and those undergoing revascularization
8–21,109–115). The preponderance of the evidence sup-
rting the use of GP IIb/IIIa inhibitor therapy predated the
ials that established the benefits of clopidogrel, early inva-
ve therapy, and contemporary medical treatments in patients
ith UA/NSTEMI. These studies supported the upstream use
a GP IIb/IIIa inhibitor as a second agent in combination
ith ASA for dual-antiplatelet therapy in patients with
A/NSTEMI, especially in high-risk subsets such as those
ith an initial elevation in cardiac troponins, those with
iabetes, and in those undergoing revascularization
9,20,25,110,111,113). These studies did not directly test in
randomized fashion the selection of an oral thienopyridine
rsus an intravenous GP IIb/IIIa inhibitor as the second
tiplatelet agent in UA/NSTEMI.
Contemporary clinical trials have therefore been needed to
fine the optimal timing of initiation of GP IIb/IIIa inhibitor
erapy in patients with UA/NSTEMI, whether “upstream”
t presentation and before angiography) or “deferred” (at the
me of angiography/PCI), and its optimal application
hether routine, selective, or provisional) and to clarify the
lative benefit and risk of GP IIb/IIIa inhibitor therapy as a
ird antiplatelet agent in combination with ASA and a
ienopyridine.
The EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition
Patients With Non–ST-Segment Elevation Acute Coronaryyndrome) trial (37) tested the hypothesis that a strategy of wrly routine administration of the GP IIb/IIIa inhibitor
tifibatide would be superior to delayed provisional admin-
tration in reducing ischemic complications among high-risk
tients with UA/NSTEMI. The study investigators enrolled
92 patients who presented within 24 hours of an episode of
chemic rest discomfort of at least 10 minutes’ duration. The
udy subjects were randomized within 8 to12 hours after
esentation and assigned to an invasive treatment strategy no
oner than the next calendar day. To qualify as having
gh-risk UA/NSTEMI, the subjects were required to have at
ast 2 of the following: ST-segment depression or transient
T-segment elevation, elevated biomarker levels (creatine
nase–MB or troponin), or age 60 years. The study
bjects were randomized in a double-blind design to receive
ther early routine administration of eptifibatide (double
lus followed by standard infusion) or delayed provisional
tifibatide at the time of PCI. Eptifibatide infusion was given
r 18 to 24 hours after PCI in both groups. For patients who
derwent PCI, the total duration of the infusion was 96
urs. For patients who did not receive PCI for whatever
ason, the duration of infusion was 96 hours. The study
fusion was stopped 2 hours before surgery for those
dergoing CABG. Early clopidogrel was allowed at the
vestigators’ discretion (75% intended early use), and if
ed, a loading dose of 300 mg was recommended. For
tients beginning clopidogrel during PCI (intended in 25%
study subjects, but actually implemented in 11%), a dose
600 mg was permitted. Randomization to 1 of 3 antithrom-
tic regimens was stratified according to the intention of the
vestigator to administer early clopidogrel (i.e., at or before
ndomization) (37).
The primary endpoint (a 30-day composite of all-cause
ath, MI, recurrent ischemia requiring urgent revasculariza-
on, or thrombotic bailout at 96 hours) occurred in 9.3% of
tients in the early therapy arm versus 10.0% of patients in
e provisional GP IIb/IIIa inhibitor therapy arm (OR: 0.92;
% CI: 0.80 to 1.06; p0.23). Secondary endpoint (all-
use death or MI within 30 days) event rates were 11.2%
rsus 12.3% (OR: 0.89; 95% CI: 0.79 to 1.01; p0.08).
arly routine eptifibatide administration was associated with
greater risk of TIMI major hemorrhage (2.6% versus 1.8%;
0.02). Severe or moderate bleeding, as defined by the
USTO (Global Utilization of Streptokinase and t-PA for
ccluded Coronary Arteries) criteria, also occurred more
mmonly in the early eptifibatide group (7.6% versus 5.1%;
0.001). Rates of red blood cell transfusion were 8.6% and
7% in the early-eptifibatide and delayed-eptifibatide groups,
spectively (p0.001). There were no significant interac-
ons with respect to prespecified baseline characteristics,
cluding early clopidogrel administration, and the primary or
condary efficacy endpoints. In a subgroup analysis, early
ministration of eptifibatide in patients who underwent PCI
as associated with numerically fewer ischemic events.
A second contemporary study, the ACUITY (Acute Cath-
erization and Urgent Intervention Triage strategY) trial
6), examined in part the optimal strategy for the use of GP
b/IIIa inhibitors in moderate- and high-risk ACS patients
dergoing early invasive therapy. A total of 9207 patientsere randomized to 1 of 3 antithrombin regimens: unfrac-
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May 10, 2011:1920–59 UA/NSTEMI Guideline Focused Updateonated heparin (UFH) or enoxaparin plus GP IIb/IIIa inhib-
or therapy; bivalirudin plus GP IIb/IIIa inhibitor therapy; or
valirudin alone. Patients assigned to the heparin (UFH or
oxaparin) plus GP IIb/IIIa inhibitor therapy or to the
valirudin plus GP IIb/IIIa inhibitor therapy were also
ndomized to immediate upstream routine GP IIb/IIIa inhib-
or therapy or deferred selective use of GP IIb/IIIa inhibitor
erapy at the time of PCI. A clopidogrel loading dose of
300 mg was required in all cases no later than 2 hours after
CI, and provisional GP IIb/IIIa inhibitor use was permitted
fore angiography in the deferred group for severe break-
rough ischemia. The composite ischemic endpoint occurred
7.1% of the patients assigned to upstream administration
d in 7.9% of patients assigned to deferred selective admin-
tration (RR: 1.12; 95% CI: 0.97 to 1.29; p0.044), and thus
e noninferiority hypothesis was not achieved. Major bleed-
g was lower in the deferred-use group versus the upstream
oup (4.9% to 6.1%; p0.001 for noninferiority and
0.009 for superiority).
Although early GP IIb/IIIa inhibitor therapy as dual-
tiplatelet therapy also reduced complications after PCI,
pporting its continued role in patients undergoing PCI
7,37,112,114,115), these 2 most recent studies more
rongly support a strategy of selective rather than provisional
e of GP IIb/IIIa inhibitor therapy as part of triple-
tiplatelet therapy. Data from EARLY ACS (37) highlight
e potential bleeding risks of upstream use of a GP IIb/IIIa
hibitor as part of triple-antiplatelet therapy. The use of a GP
b/IIIa inhibitor should be undertaken when the risk-benefit
tio suggests a potential benefit for the patient. The use of
ese agents as part of triple-antiplatelet therapy may there-
re not be supported when there is a concern for increased
eeding risk or in non–high-risk subsets such as those with
normal baseline troponin level, those without diabetes, and
ose75 years of age, in whom the potential benefit may be
gnificantly offset by the potential risk of bleeding.
.3. Recommendations for
itial Conservative Versus
itial Invasive Strategies
ee Table 4, and Appendixes 3 and 6 for supplemental
formation.)
3.3.1. TIMING OF INVASIVE THERAPY
mong initially stabilized patients with UA/NSTEMI for
hom an early invasive strategy of coronary angiography is
osen, optimal timing of angiography has not been well
fined. Early or immediate catheterization with revascular-
ation of unstable coronary lesions may prevent ischemic
ents that would otherwise occur during medical therapy.
onversely, pretreatment with intensive antithrombotic ther-
y may diminish thrombus burden and “passivate” unstable
aques, improving the safety of percutaneous revasculariza-
on and reducing the risk of periprocedural ischemic com-
ications. Three trials have compared different strategies of
arly” versus “delayed” intervention in patients with UA/
STEMI and form the basis of the updated recommendation
this guideline. stThe ISAR-COOL (Intracoronary Stenting with Antithrom-
tic Regimen Cooling-Off) trial (119) carried out at 2
spitals between 2000 and 2002 randomized 410 patients
ith unstable chest pain and either electrocardiographic
T-segment depression or elevated troponin levels to undergo
ronary angiography within 6 hours of presentation (median
4 hours) or after 3 to 5 days (median 86 hours) of
tithrombotic pretreatment (119). Patients with “large MI,”
fined by ST-segment elevation or creatine kinase–MB
oenzyme activity 3 times normal, were excluded. Under-
ing medical therapy in both treatment arms included ASA,
opidogrel, UFH, and tirofiban. By 30 days’ follow-up, the
imary endpoint of death or large MI (defined by new
ectrocardiographic Q waves, left bundle-branch block, or
eatine kinase–MB elevation 5 times normal) occurred in
.6% of patients randomized to delayed catheterization
rsus 5.9% of those in the early angiography group
0.04). Differences between treatment groups were ob-
rved exclusively in the period before catheterization, with
entical event rates in the 2 arms after angiography. Al-
ough providing evidence that a strategy of “cooling-off” for
to 5 days before angiography does not improve outcome in
is setting, the findings of this trial were limited because of
e small sample size and the prolonged delay before angiog-
phy in the medical pretreatment arm.
Information more relevant to contemporary practice pat-
rns was provided in the 2009 publication of the large-scale
ulticenter TIMACS (Timing of Intervention in Acute Cor-
ary Syndromes) trial (38), which compared early versus
layed angiography and intervention in patients with non–
T-segment elevation ACS. Patients were included if they
esented within 24 hours of onset of unstable ischemic
mptoms with advanced age (60 years), elevated cardiac
omarkers, or ischemic electrocardiographic changes, and
ere randomized to undergo angiography as rapidly as
ssible and within 24 hours of randomization (median 14
urs) versus after a minimum delay of 36 hours (median 50
urs). Anticoagulation included ASA, clopidogrel in 80%
patients, heparin or fondaparinux, and GP IIb/IIIa inhibi-
rs in 23% of patients. Although the trial was initially
wered for enrollment of 4,000 patients to detect a 25%
duction in the primary endpoint of death, new MI, or stroke
6 months, the steering committee chose to terminate
rollment at 3031 patients because of recruitment chal-
nges. Among the overall trial population, there was only a
nsignificant trend toward a reduced incidence of the pri-
ary clinical endpoint, from 11.3% in the delayed interven-
on group to 9.6% in the early intervention arm (for early
tervention: 0.85; 95% CI: 0.68 to 1.06; p0.15). However,
prospectively defined secondary endpoint of death, MI, or
fractory ischemia was significantly reduced by early inter-
ntion from 12.9% to 9.5% (HR: 0.72; 95% CI: 0.58 to 0.89;
0.003), mainly because of a difference in the incidence of
fractory ischemia (3.3% versus 1.0% in the delayed versus
rly intervention arms, respectively; p0.001). The occur-
nce of refractory ischemia was associated with a 4-fold
crease in risk of subsequent MI. Moreover, significant
terogeneity was observed in the primary endpoint whenratified according to a prespecified estimation of baseline
ri
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vents (GRACE) score. Patients in the highest tertile of the
RACE risk score (140) experienced a sizeable and sig-
ficant reduction in the incidence of the primary ischemic
dpoint, from 21.0% to 13.9% (HR: 0.65; 95% CI: 0.48 to
89; p0.006), whereas no difference in outcome (6.7%
rsus 7.6% in the delayed and early groups, respectively;
R: 1.12; 95% CI: 0.81 to 1.56; p0.48) was observed
ong patients in the lower 2 risk tertiles (GRACE score
140) (38).
Results of the TIMACS trial suggested superior outcome
ong patients managed by early rather than delayed inter-
ntion in the setting of UA/NSTEMI, although the reduction
ble 4. Recommendations for Initial Invasive Versus Initial Con
2007 Recommendations
ss I
An early invasive strategy (i.e., diagnostic angiography with intent
to perform revascularization) is indicated in UA/NSTEMI patients
who have refractory angina or hemodynamic or electrical
instability (without serious comorbidities or contraindications to
such procedures). (Level of Evidence: B)
1. An early inva
revasculariza
angina or he
or contraindi
An early invasive strategy (i.e., diagnostic angiography with intent
to perform revascularization) is indicated in initially stabilized
UA/NSTEMI patients (without serious comorbidities or
contraindications to such procedures) who have an elevated risk
for clinical events (see Table 11 and Sections 2.2.6 and 3.4.3).
(Level of Evidence: A)
2. An early inva
revasculariza
(without serio
have an elev
Sections 2.2.
ss IIa
1. It is reasonab
of admission
patients with
approach is
ss IIb
In initially stabilized patients, an initially conservative (i.e., a
selectively invasive) strategy may be considered as a treatment
strategy for UA/NSTEMI patients (without serious comorbidities or
contraindications to such procedures) who have an elevated risk
for clinical events (see Table 11 and Sections 2.2.6 and 3.4.3),
including those who are troponin positive. (Level of Evidence: B)
The decision to implement an initial conservative (vs initial
invasive) strategy in these patients may be made by considering
physician and patient preference. (Level of Evidence: C)
1. In initially sta
invasive) stra
patients (with
procedures)
Table 11 and
positive (69,1
conservative
considering p
An invasive strategy may be reasonable in patients with chronic
renal insufficiency. (Level of Evidence: C)
ss III: No Benefit
An early invasive strategy (i.e., diagnostic angiography with intent
to perform revascularization) is not recommended in patients
with extensive comorbidities (e.g., liver or pulmonary failure,
cancer), in whom the risks of revascularization and comorbid
conditions are likely to outweigh the benefits of revascularization.
(Level of Evidence: C)
1. An early inva
revasculariza
comorbidities
revasculariza
of revascular
An early invasive strategy (i.e., diagnostic angiography with intent
to perform revascularization) is not recommended in patients
with acute chest pain and a low likelihood of ACS. (Level of
Evidence: C)
2. An early inva
revasculariza
a low likeliho
An early invasive strategy (i.e., diagnostic angiography with intent
to perform revascularization) should not be performed in patients
who will not consent to revascularization regardless of the
findings. (Level of Evidence: C)
3. An early inva
revasculariza
to revascular
*Immediate catheterization/angiography is recommended for unstable patienthe primary endpoint did not reach statistical significance elr the overall trial population. Nevertheless, refractory isch-
ia was reduced by an early approach, as were the risks of
ath, MI, and stroke among patients at the highest tertile of
chemic risk as defined by the GRACE risk score (38).
To assess whether a more aggressive strategy of very early
tervention, analogous to the standard of primary PCI for
TEMI, would lead to improved outcomes in patients with
n–ST-elevation ACS, the ABOARD (Angioplasty to Blunt
e Rise of Troponin in Acute Coronary Syndromes) study
vestigators (120) compared angiography and intervention
rformed immediately on presentation with intervention
rried out on the next working day. A total of 352 patients
ith unstable ischemic symptoms, ECG changes, or troponin
ve Strategies
Focused Update Recommendations Comments
egy (i.e., diagnostic angiography with intent to perform
dicated in UA/NSTEMI patients who have refractory
ic or electrical instability (without serious comorbidities
such procedures) (116,117). (Level of Evidence: B)
2007 recommendation
remains current.
egy (i.e., diagnostic angiography with intent to perform
dicated in initially stabilized UA/NSTEMI patients
rbidities or contraindications to such procedures) who
for clinical events (see 2007 (2) Table 11 and 2007
.3) (25,26,69). (Level of Evidence: A)
2007 recommendation
remains current.
ose an early invasive strategy (within 12 to 24 hours
elayed invasive strategy for initially stabilized high-risk
MI.* For patients not at high risk, a delayed invasive
nable (38). (Level of Evidence: B)
New recommendation
(modified from 2009
STEMI and PCI Focused
Update) (32).
tients, an initially conservative (i.e., a selectively
be considered as a treatment strategy for UA/NSTEMI
us comorbidities or contraindications to such
an elevated risk for clinical events (see 2007 (2)
2.2.6 and 3.4.3), including those who are troponin
el of Evidence: B) The decision to implement an initial
invasive) strategy in these patients may be made by
and patient preference. (Level of Evidence: C)
2007 recommendation
remains current.
Recommendation moved
to Section 6.5, class
changed to IIa, level of
evidence changed to B.
egy (i.e., diagnostic angiography with intent to perform
t recommended in patients with extensive
r or pulmonary failure, cancer), in whom the risks of
omorbid conditions are likely to outweigh the benefits
evel of Evidence: C)
2007 recommendation
remains current.
egy (i.e., diagnostic angiography with intent to perform
t recommended in patients with acute chest pain and
. (Level of Evidence: C)
2007 recommendation
remains current.
egy (i.e., diagnostic angiography with intent to perform
ld not be performed in patients who will not consent
gardless of the findings. (Level of Evidence: C)
2007 recommendation
remains current.servati
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May 10, 2011:1920–59 UA/NSTEMI Guideline Focused Updateedian 70 minutes after enrollment) versus delayed (at a
edian 21 hours) angiography and revascularization. Back-
ound antithrombotic therapy consisted of ASA, clopidogrel
ith a loading dose of 300 mg, abciximab during PCI, and
e anticoagulant of the investigator’s choice. The primary
ial endpoint was peak troponin I value during the hospital-
ation period. Immediate intervention conferred no advan-
ge with regard to the primary endpoint (median troponin I
lue 2.1 versus 1.7 ng/mL in the immediate and delayed
tervention groups, respectively), nor was there even a trend
ward improved outcome in the prespecified clinical second-
y endpoint of death, MI, or urgent revascularization by 1
onth (13.7% versus 10.2%, in the immediate and delayed
tervention groups, respectively; p0.31) (120).
These 3 trials, taken together with earlier studies, do
ovide support for a strategy of early angiography and
tervention to reduce ischemic complications in patients who
ve been selected for an initial invasive strategy, particularly
ong those at high risk (defined by a GRACE score 140),
hereas a more delayed approach is reasonable in low- to
termediate-risk patients. The “early” time period in this
ntext is considered to be within the first 24 hours after
spital presentation, although there is no evidence that
cremental benefit is derived by angiography and interven-
on performed within the first few hours of hospital admis-
on. The advantage of early intervention was achieved in the
ntext of intensive background antithrombotic therapy.
. Late Hospital Care,
ospital Discharge, and
osthospital Discharge Care
.2. Long-Term Medical Therapy and
econdary Prevention
.2.1. Recommendations for Convalescent and
ong-Term Antiplatelet Therapy
ee Table 5, and Appendixes 3 and 4 for supplemental
formation.)
.2.6. Recommendations for Warfarin Therapy
ee Table 6 and Appendix 3.)
. Special Groups
.2. Recommendations for Diabetes Mellitus
ee Table 7 and Appendix 3.)
2.1.1. INTENSIVE GLUCOSE CONTROL
s detailed in the 2004 STEMI guideline (147), 2007
A/NSTEMI guideline revision (2), and 2009 STEMI and
CI focused update (32), randomized trial evidence supported
e of insulin infusion to control hyperglycemia. A clinical
ial of intensive versus conventional glucose control in
itically ill patients raised uncertainty about the optimal level
target when achieving glucose control. NICE-SUGAR
ormoglycaemia in Intensive Care Evaluation—Survivalsing Glucose Algorithm Regulation), a large international wndomized trial (n6104) of adults admitted to the intensive
re unit with either medical or surgical conditions, compared
tensive glucose control (target glucose range, 81 to 108
g/dL) with conventional glucose control (to achieve a
ucose level of 180 mg/dL, with reduction and discontin-
tion of insulin if the blood glucose level dropped below 144
g/dL) (143). Time-weighted glucose levels achieved were
518 mg/dL in the intensive group versus 14423 mg/dL
the conventional group. The risk of death was increased at
days in the intensive group by 2.6% (27.5% versus 24.9%;
R: 1.14; 95% CI: 1.02 to 1.08; p0.02; number needed to
rm38). The result remained the same after adjusting for
tential confounders. There were significantly more epi-
des of treatment-related hypoglycemia in the intensely
anaged group (6.8% versus 0.5%; p0.001), although the
ntribution of hypoglycemia to excess mortality is uncertain
43,144). Overall, the hospital course and proximate causes
death were similar in the 2 groups. Excess deaths in the
tensive management group were predominantly of cardio-
scular causes (absolute difference: 5.8%; p0.02). More
tients in the intensive group than in the conventional group
ere treated with corticosteroids.
Because NICE-SUGAR (143) enrolled critically ill medi-
l and surgical patients, the degree to which its results can be
trapolated to the management of patients with UA/
STEMI is unclear. Although recent data from a small,
echanistic clinical trial (148,149) suggest that glucose
ntrol may reduce inflammation and improve left ventricular
ection fraction (LVEF) in patients with acute MI, it remains
certain whether acute glucose control will improve patient
tcomes.
A consensus statement by the American Association of
linical Endocrinologists and the American Diabetes Asso-
ation (150) summarized that “although hyperglycemia is
sociated with adverse outcomes after acute MI, reduction of
ycemia per se and not necessarily the use of insulin is
sociated with improved outcomes. It remains unclear,
wever, whether hyperglycemia is a marker of underlying
alth status or is a mediator of complications after acute MI.
oniatrogenic hypoglycemia has also been associated with
verse outcomes and is a predictor of higher mortality.”
There is a clear need for a well-designed, definitive
ndomized trial of target-driven glucose control in UA/
STEMI patients with meaningful clinical endpoints so that
ucose treatment thresholds and glucose targets can be
termined. Until such a trial is completed, and on the basis
the balance of current evidence (150–152), the writing
oup concluded that it was prudent to change the recom-
endation for the use of insulin to control blood glucose in
A/NSTEMI from a more stringent to a more moderate
rget range in keeping with the recent 2009 STEMI and PCI
ocused Update (Class IIa, Level of Evidence: B) (32) and
commend treatment for hyperglycemia 180 mg/dL while
oiding hypoglycemia. The writing group believed that the
07 recommendation(2) regarding long-term glycemic con-
ol targets failed to reflect recent data casting doubt on a
ecific ideal goal for the management of diabetes in patients
ith UA/NSTEMI.
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UA/NSTEMI Guideline Focused Update May 10, 2011:1920–59ble 5. Recommendations for Convalescent and Long-Term Antiplatelet Therapy
2007 Recommendations 2011 Focused Update Recommendations Comments
ass I
For UA/NSTEMI patients treated medically without stenting, ASA*
(75 to 162 mg per day) should be prescribed indefinitely (Level
of Evidence: A); clopidogrel† (75 mg per day) should be
prescribed for at least 1 month (Level of Evidence: A) and
ideally for up to 1 year. (Level of Evidence: B)
1. For UA/NSTEMI patients treated medically without stenting,
ASA* (75 to 162 mg per day) should be prescribed indefinitely
(4,6,9,10) (Level of Evidence: A); clopidogrel† (75 mg per
day) should be prescribed for at least 1 month (13) and
ideally up to 1 year (13,121). (Level of Evidence: B)
Modified recommendation (level of
evidence changed from A to B for
1-month duration of clopidogrel).
For UA/NSTEMI patients treated with a BMS, ASA* 162 to 325
mg per day should be prescribed for at least 1 month (Level of
Evidence: B), then continued indefinitely at a dose of 75 to 162
mg per day (Level of Evidence: A); clopidogrel should be
prescribed at a dose of 75 mg per day for a minimum of 1
month and ideally for up to 1 year (unless the patient is at
increased risk of bleeding; then it should be given for a
minimum of 2 weeks). (Level of Evidence: B)
2. For UA/NSTEMI patients treated with a BMS, ASA* 162 to
325 mg per day should be prescribed for at least 1 month
(Level of Evidence: B), then continued indefinitely at a dose
of 75 to 162 mg per day. (Level of Evidence: A) The
duration and maintenance dose of thienopyridine therapy
should be as follows:
a. Clopidogrel 75 mg daily (17) or prasugrel† 10 mg daily
(22) should be given for at least 12 months (13,17).
(Level of Evidence: B)
b. If the risk of morbidity because of bleeding outweighs
the anticipated benefits afforded by thienopyridine
therapy, earlier discontinuation should be considered.
(Level of Evidence: C)
Modified recommendation (to be
concordant with 2009 STEMI and
PCI Focused Update [32]).
For UA/NSTEMI patients treated with a DES, ASA* 162 to 325
mg per day should be prescribed for at least 3 months after
sirolimus-eluting stent implantation and 6 months after
paclitaxel-eluting stent implantation, then continued indefinitely
at a dose of 75 to 162 mg per day. (Level of Evidence: B)
Clopidogrel 75 mg daily should be given for at least 12 months
to all post-PCI patients receiving DES. (Level of Evidence: B)
3. For UA/NSTEMI patients treated with a DES, ASA* 162 to
325 mg per day should be prescribed for at least 3 months
after sirolimus-eluting stent implantation and 6 months after
paclitaxel-eluting stent implantation (Level of Evidence: B),
then continued indefinitely at a dose of 75 to 162 mg per
day. (Level of Evidence: A). The duration and maintenance
dose of thienopyridine therapy should be as follows:
a. Clopidogrel 75 mg daily (17) or prasugrel† 10 mg daily
(22) should be given for at least 12 months (13,17).
(Level of Evidence: B)
b. If the risk of morbidity because of bleeding outweighs
the anticipated benefits afforded by thienopyridine
therapy, earlier discontinuation should be considered.
(Level of Evidence: C)
Modified recommendation (to be
concordant with 2009 STEMI and
PCI Focused Update [32]).
Clopidogrel 75 mg daily (preferred) or ticlopidine (in the absence
of contraindications) should be given to patients recovering from
UA/NSTEMI when ASA is contraindicated or not tolerated
because of hypersensitivity or gastrointestinal intolerance (but
with gastroprotective agents such as PPIs). (Level of Evidence: A)
4. Clopidogrel 75 mg daily (preferred) or ticlopidine (in the absence
of contraindications) should be given to patients recovering from
UA/NSTEMI when ASA is contraindicated or not tolerated
because of hypersensitivity or GI intolerance (despite use of
gastroprotective agents such as PPIs) (11,61,108). (Level of
Evidence: A)
Modified recommendation
(changed wording for clarity).
ass IIa
For UA/NSTEMI patients in whom the physician is concerned
about the risk of bleeding, a lower initial ASA dose after PCI of
75 to 162 mg per day is reasonable. (Level of Evidence: C)
1. For UA/NSTEMI patients in whom the physician is concerned
about the risk of bleeding, a lower initial ASA dose (75 to 162
mg/day) after PCI is reasonable. (Level of Evidence: C)
2007 recommendation remains
current.
ass IIb
For UA/NSTEMI patients who have an indication for
anticoagulation, the addition of warfarin‡ may be reasonable to
maintain an INR of 2.0 to 3.0.§ (Level of Evidence: B)
1. For UA/NSTEMI patients who have an indication for
anticoagulation, the addition of warfarin‡ may be reasonable to
maintain an INR of 2.0 to 3.0.§ (122–131) (Level of Evidence: B)
2007 recommendation remains
current.
2. Continuation of clopidogrel or prasugrel beyond 15 months may
be considered in patients following DES placement. (Level of
Evidence: C)
New recommendation
ass III: No Benefit
Dipyridamole is not recommended as an antiplatelet agent in
post-UA/NSTEMI patients because it has not been shown to be
effective. (Level of Evidence: A)
1. Dipyridamole is not recommended as an antiplatelet agent in
post-UA/NSTEMI patients because it has not been shown to be
effective (44,132,133). (Level of Evidence: B)
Modified recommendation (level of
evidence changed from A to B).
*For ASA-allergic patients, use clopidogrel alone (indefinitely) or try ASA desensitization.
†For clopidogrel-allergic patients, use ticlopidine 250 mg by mouth twice daily.
‡Continue ASA indefinitely and warfarin longer term as indicated for specific conditions such as atrial fibrillation; LV thrombus; or cerebral, venous, or pulmonary
boli.
§An INR of 2.0 to 2.5 is preferable while given with ASA and clopidogrel, especially in older patients and those with other risk factors for bleeding. For UA/NSTEMI
tients who have mechanical heart valves, the INR should be at least 2.5 (based on type of prosthesis).
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May 10, 2011:1920–59 UA/NSTEMI Guideline Focused UpdateDiabetes is another characteristic associated with high risk
r adverse outcomes after UA/NSTEMI. The 2007 UA/
STEMI guidelines (2) state that patients with diabetes are at
gh risk and in general should be treated similarly to patients
ith other high-risk features. However, the 2011 writing
oup noted that diabetes was not listed as a high-risk feature
r which an invasive strategy was specifically preferred, in
ble 6. Recommendations for Warfarin Therapy
2007 Recommendations
ass I
Use of warfarin in conjunction with ASA and/or clopidogrel is
associated with an increased risk of bleeding and should be
monitored closely. (Level of Evidence: A)
1. Use o
thieno
of ble
bleedi
evalua
(Level
ass IIb
Warfarin either without (INR 2.5 to 3.5) or with low-dose ASA
(75 to 81 mg per day; INR 2.0 to 2.5) may be reasonable for
patients at high CAD risk and low bleeding risk who do not
require or are intolerant of clopidogrel. (Level of Evidence: B)
1. Warfa
ASA (
reason
bleedi
clopid
ble 7. Recommendations for Diabetes Mellitus
2007 Recommendations
ass I
Medical treatment in the acute phase of UA/NSTEMI and decisions on
whether to perform stress testing, angiography, and revascularization
should be similar in patients with and without diabetes mellitus.
(Level of Evidence: A)
1. M
an
an
in
(2
In all patients with diabetes mellitus and UA/NSTEMI, attention should
be directed toward aggressive glycemic management in accordance
with current standards of diabetes care endorsed by the American
Diabetes Association and the American College of Endocrinology.
Goals of therapy should include a preprandial glucose target of 110
mg per dL and a maximum daily target of 180 mg per dL. The
postdischarge goal of therapy should be HbA1C 7%, which should
be addressed by primary care and cardiac caregivers at every visit.
(Level of Evidence: B)
An IV GP IIb/IIIa inhibitor should be administered for patients with
diabetes mellitus as recommended for all UA/NSTEMI patients
(Section 3.2). (Level of Evidence: A) The benefit may be enhanced in
patients with diabetes mellitus. (Level of Evidence: B)
ass IIa
For patients with UA/NSTEMI and multivessel disease, CABG with use
of the internal mammary arteries can be beneficial over PCI in
patients being treated for diabetes mellitus. (Level of Evidence: B)
1. Fo
di
ar
tre
Ev
PCI is reasonable for UA/NSTEMI patients with diabetes mellitus with
single-vessel disease and inducible ischemia. (Level of Evidence: B)
2. PC
di
in
In patients with UA/NSTEMI and diabetes mellitus, it is reasonable to
administer aggressive insulin therapy to achieve a glucose 150 mg
per dL during the first 3 hospital (intensive care unit) days and
between 80 and 110 mg per dL thereafter whenever possible. (Level
of Evidence: B)
3. It
ac
w
pa
or
Ev*There is uncertainty about the ideal target range for glucose necessary to achieventrast to the inclusion of chronic kidney disease (CKD) and
abetes mellitus as characteristics favoring an invasive
proach in the 2007 European Society of Cardiology guide-
nes for management of UA/NSTEMI (153). To revisit this
estion for diabetes, the writing group reviewed results of
e published analysis of patients with diabetes in the
RISC-II (FRagmin and Fast Revascularization during InSta-
ocused Update Recommendations Comments
in in conjunction with ASA and/or a
agent is associated with an increased risk
nd patients and clinicians should watch for
cially gastrointestinal, and seek medical
evidence of bleeding (13,22,86,134–137).
ence: A)
Modified recommendation
(updated to include a
choice of thienopyridine).
r without (INR 2.5 to 3.5) or with low-dose
mg per day; INR 2.0 to 2.5) may be
r patients at high CAD risk and low
who do not require or are intolerant of
38,139). (Level of Evidence: B)
2007 recommendation
remains current.
Focused Update Recommendations Comments
eatment in the acute phase of UA/NSTEMI
ons on whether to perform stress testing,
y, and revascularization should be similar
with and without diabetes mellitus
140). (Level of Evidence: A)
2007 recommendation remains
current.
Deleted recommendation (defer
to American Diabetes
Association Guidelines [141]).
Deleted recommendation
(deleted to avoid redundancy;
refer to Tables 2 and 3).
ts with UA/NSTEMI and multivessel
ABG with use of the internal mammary
n be beneficial over PCI in patients being
diabetes mellitus (142). (Level of
B)
2007 recommendation remains
current.
onable for UA/NSTEMI patients with
ellitus with single-vessel disease and
schemia (25,142). (Level of Evidence: B)
2007 recommendation remains
current.
nable to use an insulin-based regimen to
d maintain glucose levels  180 mg/dL
ding hypoglycemia* for hospitalized
ith UA/NSTEMI with either a complicated
licated course (143–146). (Level of
B)
Modified recommendation
(language changed to be
concordant with 2009 STEMI
and PCI Focused Update [32]).2011 F
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UA/NSTEMI Guideline Focused Update May 10, 2011:1920–59lity in Coronary artery disease) trial (26). Overall, the
RISC II trial demonstrated a benefit with invasive manage-
ent compared with conservative management in patients
ith UA/NSTEMI. There were similar reductions in the risk
MI/death at 1 year in the diabetic subgroup randomized to
invasive strategy (OR: 0.61 [0.36 to 1.04]) compared with
tients who did not have diabetes randomized to an invasive
rategy (OR: 0.72 [0.54 to 0.95]). The risk of death was also
duced by randomization to an invasive strategy among
tients with diabetes (OR: 0.59 [95% CI: 0.27 to 1.27]) and
ithout diabetes (OR: 0.50 [95% CI: 0.27 to 0.94]). Subgroup
alysis of the TACTICS-TIMI-18 (Treat Angina with ag-
astat and determine Cost of Therapy with Invasive or
onservative Strategy–Thrombolysis In Myocardial Infarc-
on 18) study in patients with diabetes, available in abstract
rm, was consistent with this finding (154). Thus, diabetes,
well as the often concurrent comorbidity of CKD (Section
5, “Recommendations for Chronic Kidney Disease”), is not
ly a high-risk factor but also benefits from an invasive
proach. Accordingly, diabetes has been added to the list of
aracteristics for which an early invasive strategy is gener-
ly preferred (Appendix 8).
.5. Recommendations for
hronic Kidney Disease
ee Table 8, and Appendixes 3 and 7 for supplemental
formation.)
.5.1. Angiography in Patients With
hronic Kidney Disease
ince the 2007 UA/NSTEMI Guidelines were published (2),
veral larger randomized trials have been published that
ported no difference in contrast-induced nephropathy (CIN)
hen iodixanol was compared with various other low-
ble 8. Recommendations for Chronic Kidney Disease
2007 Recommendations
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CrCl should be estimated in UA/NSTEMI patients, and the doses
of renally cleared drugs should be adjusted appropriately. (Level
of Evidence: B)
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UA/Nmolar contrast media (LOCM) (163–166). These and other hondomized trials comparing isosmolar iodixanol with
OCM have been summarized in 2 mutually supportive and
mplementary meta-analyses involving 16 trials in 2763
tients (167) and 25 trials in 3260 patients (168), respec-
vely. When more recent trials were combined with the older
udies, the data supporting a reduction in CIN favoring
dixanol were no longer significant (summary RR: 0.79;
% CI: 0.56 to 1.12; p0.29(167); summary RR: 0.80; 95%
I: 0.61 to 1.04; p0.10 (168), respectively). However,
banalyses showed variations in relative renal safety by
ecific LOCM: A reduction in CIN was observed when
dixanol was compared to ioxaglate, the only ionic LOCM
R: 0.58; 95% CI: 0.37 to 0.92; p0.022 [167]), and to
hexol, a nonionic LOCM (RR: 0.19; 95% CI: 0.07 to 0.56;
0.0002 [167]), but no difference was noted in comparisons
iodixanol with iopamidol, iopromide, or ioversol (167),
d a single trial favored iomeprol (166). A pooled compar-
on of iodixanol with all nonionic LOCM other than iohexol
dicated equivalent safety (RR: 0.97; 95% CI: 0.72 to 1.32;
0.86 [168]). Results were consistent regardless of ancil-
ry preventive therapies (hydration, acetylcysteine), route of
ministration (intravenous or intra-arterial), age, sex, dose,
preexisting CKD or diabetes. Of further interest, findings
ere similar in the 8 studies (n1,793 patients) performed in
e setting of coronary angiography (167). These results have
en incorporated into the 2009 STEMI/PCI Focused Update
commendations (32). A more recent study comparing
dixanol versus iopamidol provides additional supportive
idence (169). However, even these clinical inferences must
tempered by the relative paucity of head-to-head trials
mparing CIN rates among the various contrast media and
e variability in results (e.g., for iohexol versus other
w-osmolar comparators) (170–173). Further, the assump-
on that a transient rise in serum creatinine after 24 to 48
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ally cleared medications should be adjusted
the pharmacokinetic data for specific
(155,156). (Level of Evidence: B)
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,162). (Level of Evidence: B) (There are
ata on benefit/risk of invasive strategy in
atients with advanced CKD [stages IV, V].)
Modified recommendation
(class changed from IIb to
IIa, level of evidence
changed from C to B, and
moved from Section 3.3).2011
should
s of ren
rding to
ications
nts und
ntrast m
ation (15
ulation o
edict th
be given
rast-ass
nce: B)
vasive
e II) and
,156,161
ficient d
STEMI purs is a reliable predictor of the more serious but somewhat
de
or
su
na
pa
(0
ob
an
pr
ho
an
to
ov
pr
an
or
su
co
th
is
pr
of
ot
re
re
ci
cl
be
re
so
bi
la
ad
w
w
hy
fo
re
fu
li
si
a
pa
cr
pe
cr
co
(m
et
li
(1
ra
T
gr
ha
H
ap
fo

re
di
af
(b
N
ye
m

(2
in
iz
m
pa
(e
10
(2
p
95
th
(2
or
di
p
su
C
en
no
de
ot
w
re
co
tr
ef
(1
eg
iz
co
no
m
M
co
1.
di
ti
m
po
w
ta
th
1939JACC Vol. 57, No. 19, 2011 Wright et al.
May 10, 2011:1920–59 UA/NSTEMI Guideline Focused Updatelayed development of renal failure requiring hospitalization
dialysis has been challenged. A nationwide Swedish
rvey (174) of hospitalizations for renal failure after coro-
ry procedures in 57,925 patients found that this risk was
radoxically higher with iodixanol (1.7%) than ioxaglate
.8%) or iohexol (0.9%; p0.001). Although the result was
servational, hence subject to selection bias, it persisted in
alyses of high-risk patient subsets (patients with diabetes,
ior history of renal failure), in multivariable analysis, and in
spitals crossing over from ioxaglate to iodixanol. Iodix-
ol’s greater viscosity was speculated but not demonstrated
be a possible mechanism for the observed effect. Thus, an
erall summary of the current database, updated since
evious guideline recommendations (2,32), is that strength
d consistency of relationships between specific isosmolar
low-osmolar agents and CIN or renal failure are not
fficient to enable a guideline statement on selection among
mmonly used low-osmolar and isosmolar media. Instead,
e writing group recommends focusing on operator conduct
sues shown to be important to protect patients, that is, 1)
oper patient preparation with hydration, and 2) adjustment
maximal contrast dose to each patient’s renal function and
her clinical characteristics.
With respect to patient preparation, the writing group
viewed several trials addressing the optimal preparatory
gimen of hydration and pharmacotherapy. The basic prin-
ple of hydration follows from experimental studies and
inical experience, with isotonic or half-normal saline alone
ing the historical gold standards (157,158,175–177). More
cently, sodium bicarbonate has been tested as the hydrating
lution. Some trials have reported superiority of sodium
carbonate over saline in preventing CIN (178–181). Simi-
rly, some have reported a benefit of N-acetylcysteine
ministration as adjunctive therapy to hydration (178,182),
hereas others have not (183,184). Thus, although the
riting group found the evidence compelling for adequate
dration preparatory to angiography with contrast media, it
und the evidence insufficient to recommend a specific
gimen.
With respect to limitation of contrast dose by renal
nction, mounting evidence points to renal-function–specific
mits on maximal contrast volumes that can be given without
gnificantly increasing the baseline risk of provoking CIN. In
contemporary study, Laskey et al studied 3179 consecutive
tients undergoing PCI and found that a contrast volume to
eatinine clearance ratio 3.7 was a significant and inde-
ndent predictor of an early and abnormal increase in serum
eatinine (160). In an earlier trial, administration of a
ntrast volume of 5 mLbody weight (kg)/serum creatinine
g/dL), applied to 16,592 patients undergoing cardiac cath-
erization, was associated with a 6-fold increase in the
kelihood of patients developing CIN requiring dialysis
59).
Patients with CKD are consistently underrepresented in
ndomized controlled trials of cardiovascular disease (185).
he impact of an invasive strategy has been uncertain in this
oup. The SWEDEHEART (Swedish Web-System for En-
ncement and Development of Evidence-Based Care in
eart Disease Evaluated According to Recommended Ther- seies) study included a cohort of 23,262 patients hospitalized
r NSTEMI in Sweden between 2003 and 2006 who were
80 years of age (161). This contemporary nationwide
gistry of nearly all consecutive patients examined the
stribution of CKD and the use of early revascularization
ter NSTEMI and evaluated whether early revascularization
y either PCI or CABG) within 14 days of admission for
STEMI altered outcomes at all stages of kidney function.
In SWEDEHEART, all-cause mortality was assessed at 1
ar and was available in 99% of patients. Moderate or
ore advanced CKD (estimated glomerular filtration rate
60 mL/min per 1.73 m2) was present in 5689 patients
4.4%). After multivariable adjustment, the 1-year mortality
the overall cohort was 36% lower with early revascular-
ation (HR: 0.64; 95% CI: 0.56 to 0.73; p0.001) (161). The
agnitude of the difference in 1-year mortality was similar in
tients with normal estimated glomerular filtration rate
arly revascularization versus medically treated: 1.9% versus
%; HR: 0.58; 95% CI: 0.42 to 0.80; p0.001), mild CKD
.4% versus 10%; HR: 0.64; 95% CI: 0.52 to 0.80;
0.001), and moderate CKD (7% versus 22%; HR: 0.68;
% CI: 0.54 to 0.86; p0.001). The benefit of an invasive
erapy was not evident in patients with severe CKD stage IV
2% versus 41%; HR: 0.91; 95% CI: 0.51 to 1.61; p0.780)
in those with CKD stage V kidney failure or receiving
alysis (44% versus 53%; HR: 1.61; 95% CI: 0.84 to 3.09;
0.150). Early revascularization was associated with 1-year
rvival in UA/NSTEMI patients with mild to moderate
KD, but no association was observed in those with severe or
d-stage kidney disease (161).
The findings from SWEDEHEART are limited by their
nrandomized nature and the potential for selection bias
spite the intricate multivariable adjustment (161). On the
her hand, SWEDEHEART captured unselected patients
ith more comorbidities and is therefore more reflective of
al-world patients.
Recently, a collaborative meta-analysis of randomized
ntrolled trials that compared invasive and conservative
eatments in UA/NSTEMI was conducted to estimate the
fectiveness of early angiography in patients with CKD
62). The meta-analysis demonstrated that an invasive strat-
y was associated with a significant reduction in rehospital-
ation (RR: 0.76; 95% CI: 0.66 to 0.87; p0.001) at 1 year
mpared with conservative strategy. The meta-analysis did
t show any significant differences with regard to all-cause
ortality (RR: 0.76; 95% CI: 0.49 to 1.17; p0.21), nonfatal
I (RR: 0.78; 95% CI: 0.52 to 1.16; p0.22), and the
mposite of death/nonfatal MI (RR: 0.79; 95% CI: 0.53 to
18; p0.24) (162).
Our recommendation is that an early invasive strategy (i.e.,
agnostic angiography with intent to perform revasculariza-
on) is a reasonable strategy in patients with mild and
oderate CKD. Clinicians should exercise judgment in all
pulations with impaired kidney function when considering
hether to implement an invasive strategy. Such implemen-
tion should be considered only after careful assessment of
e risks, benefits, and alternatives for each individual patient.
The observational data with regard to patients with mild to
vere CKD also support the recognition that CKD is an
un
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UA/NSTEMI Guideline Focused Update May 10, 2011:1920–59derappreciated high-risk characteristic in the UA/NSTEMI
pulation. The increased risk of mortality associated with
ild, moderate, and severe CKD remains evident across
udies (155,156,162,186). Indeed, the risks of short- and
ng-term mortality are increased as the gradient of renal
sfunction worsens (156,162,186). The optimal role of early
vascularization in this heterogeneous population of patients
mains an important topic of research and investigation as
scussed earlier in this update.
. Conclusions and Future Directions
.1. Recommendation for Quality of Care and
utcomes for Acute Coronary Syndromes
EW SECTION)
ee Table 9 and Appendix 3.)
.1.1. Quality Care and Outcomes
he development of regional systems of ACS care is a matter
utmost importance (187–189). This includes encouraging
e participation of key stakeholders in collaborative efforts to
aluate care using standardized performance and quality-
provement measures, such as those endorsed by the ACC
d the AHA for ACS (189). Standardized quality-of-care
ta registries designed to track and measure outcomes,
mplications, and adherence to evidence-based processes of
re for ACS are also critical: programs such as the NCDR
ational Cardiovascular Data Registry) ACTION Registry-
WTG, the AHA’s Get With The Guidelines (GWTG)
ality-improvement program, and those performance-
easurement systems required by the Joint Commission and
e Centers for Medicare and Medicaid Services (190–193).
ore recently the AHA has promoted its Mission: Lifeline
itiative, which was developed to encourage closer cooper-
ion and trust among prehospital emergency services per-
nnel and cardiac care professionals (190). The evaluation of
ble 9. Recommendation for Quality Care and Outcomes for Ac
07 Recommendation 2011 Focused Up
ass IIa
1. It is reasonable for clinicians and hospita
to participate in a standardized quality-o
measure outcomes, complications, and a
and quality improvement for UA/NSTEMICS care delivery across traditional care-delivery boundaries
ith these tools and other resources is imperative to identify
stems problems and enable the application of modern
ality-improvement methods, such as Six Sigma, to make
cessary improvements (194–197). The quality improve-
ent data coming from registries like the ACTION-GTWG
ay prove pivotal in addressing opportunities for quality
provement at the local, regional, and national level, includ-
g the elimination of healthcare disparities and conduct of
mparative effectiveness research.
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der the preceding definition. Relationships in this table are modest unless otherwise noted. Names are listed in alphabetical order within each category of review.
*Significant relationship.
AAFP indicates American Academy of Family Physicians; ACCF, American College of Cardiology Foundation; ACEP, American College of Emergency Physicians; ACP,
erican College of Physicians; AHA, American Heart Association; DSMB, data safety monitoring board; NIH, National Institutes of Health; SCAI, Society for
rdiovascular Angiography and Interventions; STS, Society of Thoracic Surgeons; Sub-I, subinvestigator; and TIMI, Thrombolysis in Myocardial Infarction.
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Sacute coronary syndrome
Tactivated clotting time
Aaspirin
Sbare-metal stent
BGcoronary artery bypass graft
Dcoronary artery disease
Ncontrast-induced nephropathy
Dchronic kidney disease
-MBcreatine kinase-myocardial band
Clcreatinine clearance
Sdrug-eluting stent
AFood and Drug Administration
glycoprotein
heart failure
Rinternational normalized ratio
intravenous
CMlow-osmolar contrast media
left ventricular
EFleft ventricular ejection fraction
Imyocardial infarction
TEMInon–ST-segment elevation myocardial infarction
Ipercutaneous coronary intervention
Iproton-pump inhibitor
EMIST-elevation myocardial infarction
Atransient ischemic attack
MIThrombolysis In Myocardial Infarction
Itroponin I
Ttroponin T
unstable angina
/NSTEMIunstable angina/non–ST-elevation myocardial infarction
Hunfractionated heparin
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Drug*
During PCI
Comments
–All Patients to Receive ASA (162–325 mg)
Patient Received Initial Medical
Treatment (With a Thienopyridine)
Patient Did Not Receive Initial Medical
Treatment (With a Thienopyridine)
IIb/IIIa receptor
antagonists
Abciximab Of uncertain benefit LD of 0.25 mg/kg IV bolus
MD of 0.125 mcg/kg per min (maximum 10
mcg/min) (Class I, LOE: A)
–Continue for up to 12 h at the discretion of the physician (198,199).
Eptifibatide Of uncertain benefit LD of 180 mcg/kg IV bolus followed 10 min
later by second IV bolus of 180 mcg/kg
MD of 2.0 mcg/kg per min, started after
first bolus; reduce infusion by 50% in
patients with estimated creatinine clearance
50 mL/min (Class I, LOE: A)
–An LD of eptifibatide is FDA approved when the medication is initiated in UA/
NSTEMI patients who are started on medical therapy and when there is an
appreciable delay to angiography/PCI: LD of 180 mcg/kg IV bolus followed by MD
of 2.0 mcg/kg per min started after bolus; reduce infusion by 50% in patients
with estimated creatinine clearance 30 mL/min (Class I, LOE:B).
–Infusion should be continued for 12 to 18 h at the discretion of the physician
(198).
Tirofiban Of uncertain benefit LD of 25 mcg/kg IV bolus
MD of IV infusion of 0.15 mcg/kg per min;
reduce rate of infusion by 50% in patients
with estimated creatinine clearance 30
mL/min (Class I, LOE: B)
–Increased dosing over previous recommendation (199,202).
–Continue for up to 18 h at the discretion of the physician (202).
–A lower-dose regimen for tirofiban is FDA approved and has been shown to be
effective when used to treat UA/NSTEMI patients who are started on medical
therapy and when there is a substantial delay to angiography/PCI (e.g., 48 h): LD
of 50 mcg/mL administered at an initial rate of 0.4 mcg/kg per min for 30
minMD of a continuous infusion of 0.1 mcg/kg per min. Continue the infusion
through angiography and for 12 to 24 h after angioplasty or atherectomy (19).
ienopyridines
Clopidogrel† If 600 mg given orally, then no additional
treatment.
A second LD of 300 mg may be given
orally to supplement a prior LD of
300 mg (Class I, LOE: C)
LD of 300–600 mg orally (Class I, LOE: A)
MD of 75 mg orally per d (Class I, LOE: A)
An MD of 150 mg orally per d for initial 6 d
may be considered (Class IIb, LOE: B)
–Optimum LD requires clinical consideration.
–Dose for patients 75 y of age has not been established.
–There is a recommended duration of therapy for all post-PCI patients receiving
a BMS or DES.
–Period of withdrawal before surgery should be at least 5 d. (For full
explanations, see footnote.)
Prasugrel‡ No data are available to guide decision
making
LD of 60 mg orally
MD of 10 mg orally per d (Class I, LOE: B)
–There is no clear need for treatment with prasugrel before PCI.
–MD of 5 mg orally per d in special circumstances.
–Special dosing for patients 60 kg.
–There is a recommended duration of therapy for all post-PCI patients receiving
a DES.
–Prasugrel is generally not recommended for patients 75 y of age because of
increased bleeding risk and uncertain benefit compared with clopidogrel.
–Contraindicated for use in patients with prior history of TIA or stroke. (For full
explanations, see footnote.)
renteral
anticoagulants
Bivalirudin For patients who have received UFH,
wait 30 min, then give 0.75 mg/kg
bolus, then 1.75 mg/kg per h infusion
(Class I, LOE: B)
0.75 mg/kg bolus, 1.75 mg/kg per h
infusion
–Bivalirudin may be used to support PCI and UA/NSTEMI with or without
previously administered UFH with the addition of 600 mg of clopidogrel (198).
–In UA/NSTEMI patients undergoing PCI who are at high risk of bleeding,
bivalirudin anticoagulation is reasonable (198).
UFH IV GP IIb/IIIa planned: target ACT
200–250 s
No IV GP IIb/IIIa planned: target ACT
250–300 s for HemoTec, 300–350 s for
Hemochron (Class I, LOE: B)
IV GP IIb/IIIa planned: 50–70 units/kg bolus
to achieve an ACT of 200–250 s.
No IV GP IIb/IIIa planned: 70–100 units/kg
bolus to achieve target ACT of 250–300 s
for HemoTec, 300–350 s for Hemochron
(Class I, LOE: B)
ACT indicates activated clotting time; ASA, aspirin; BMS, bare-metal stent; CABG, coronary artery bypass graft; DES, drug-eluting stent; FDA, Food and Drug
ministration; GP, glycoprotein; IV, intravenous; LD, loading dose; LOE, level of evidence; MACE, major adverse cardiac events; MD, maintenance dose; MI, myocardial
farction; NSTEMI, non–ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; PPI, proton pump inhibitor; STEMI, ST-elevation myocardial
farction; TIA, transient ischemic attack; UA/NSTEMI, unstable angina/non–ST-elevation myocardial infarction; and UFH, unfractionated heparin.
*This list is in alphabetical order and is not meant to indicate a particular therapy preference. This drug table does not make recommendations for combinations
listed drugs. It is only meant to indicate an approved dosage if a drug is chosen for a given situation.
†The optimum LD of clopidogrel has not been established. Randomized trials establishing its efficacy and providing data on bleeding risks used an LD of 300 mg
ally followed by a daily oral dose of 75 mg (22,203). Higher oral LDs such as 600 mg or 900 mg (204) of clopidogrel more rapidly inhibit platelet aggregation
d achieve a higher absolute level of inhibition of platelet aggregation, but the additive clinical efficacy and safety of higher oral LD have not been rigorously
tablished. For post-PCI patients receiving a DES, a daily MD should be given for at least 12 mo unless the risk of bleeding outweighs the anticipated net benefit
forded by a thienopyridine. For post-PCI patients receiving a BMS, an MD should be given for a minimum of 1 mo (98) and ideally up to 12 mo (unless the risk
bleeding outweighs the anticipated net benefit afforded by a thienopyridine; then it should be given for a minimum of 2 wks). The necessity for giving an LD of
opidogrel before PCI is driven by the pharmacokinetics of clopidogrel, for which a period of several hours is required to achieve desired levels of platelet inhibition.
tients who have a reduced-function CYP2C19 allele have significantly lower levels of the active metabolite of clopidogrel, diminished platelet inhibition, and a higher
te of MACE, including stent thrombosis (81). In NSTEMI patients taking clopidogrel for whom CABG is planned and can be delayed, it is reasonable to discontinue
e clopidogrel to allow for dissipation of the antiplatelet effect unless the urgency for revascularization and/or the net benefit of clopidogrel outweigh the potential
ks of excess bleeding. The period of withdrawal should be at least 5 d in patients receiving clopidogrel (59).
‡Patients weighing60 kg have an increased exposure to the active metabolite of prasugrel and an increased risk of bleeding on a 10-mg once–daily maintenance
se. Consideration should be given to lowering the maintenance dose to 5 mg in patients who weigh 60 kg, although the effectiveness and safety of the 5-mg
se have not been studied prospectively. For post-PCI patients receiving a BMS or DES, a daily maintenance dose should be given for at least 12 mo and for up
15 mo unless the risk of bleeding outweighs the anticipated net benefit afforded by a thienopyridine. Do not use prasugrel in patients with active pathological
eeding or a history of TIA or stroke. In patients75 y of age, prasugrel is generally not recommended because of the increased risk of fatal and intracranial bleeding
d uncertain benefit except in high-risk situations (patients with diabetes or a history of prior MI) in which its effect appears to be greater and its use may be
nsidered. Do not start prasugrel in patients likely to undergo urgent CABG. When possible, discontinue prasugrel at least 7 d before any surgery (35). Additional
k factors for bleeding include body weight 60 kg, propensity to bleed, and concomitant use of medications that increase the risk of bleeding (e.g., warfarin,
parin, fibrinolytic therapy, or chronic use of nonsteroidal anti-inflammatory drugs) (35).
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Clopidogrel Prasugrel
armacology Prodrug—requires conversion to active metabolite that irreversibly blocks
P2Y12 receptor.
Prodrug—requires conversion to active metabolite that irreversibly
blocks P2Y12 receptor. Conversion to active metabolite occurs more
rapidly and to a greater degree than with clopidogrel.
ect on platelet
Aggregation
There is a delay of several hours before maximal antiplatelet effect is seen. Onset of antiplatelet effect is faster and extent of inhibition of
aggregation is greater than with clopidogrel.
nagement strategy Conservative Invasive Conservative Invasive
Loading dose 300 mg 300–600 mg* Generally not recommended
for precatheterization use in
UA/NSTEMI
60 mg
Comment *Optimal dose not established for invasive strategy although 600 mg
generally preferred.
Timing Initiate on presentation. Give as soon as possible before
or at the time of PCI.
Initiate as soon as coronary
anatomy is known and
decision is made to
proceed with PCI
Maintenance dose 75 mg 75 mg 10 mg
Comment Optimal approach to dosing in
individual patients based on
genotype and individual
antiplatelet effects not
rigorously established.
Optimal individual dose not
rigorously established (see
comment to left). (150 mg for
first 6 d is an alternative.)
Consider reduction to 5 mg
in patients weighing 60
kg. The efficacy (or benefit)
of prasugrel in those age
75 y is uncertain.
Contraindicated in patients
with a history of stroke or
TIA.
Duration At least 1 mo and ideally up
to 1 y
At least 1 y for DES At least 1 y for DES
ditional considerations
Variability of
Response
Greater compared with prasugrel. Factors impacting response in some
patients may include genetic predisposition to convert parent compound to
active metabolite and drug interactions (e.g., PPIs).
Less compared with clopidogrel. Impact of genotype and
concomitant medications appears less than with clopidogrel.
Platelet function
Testing
Clinical utility not rigorously established. May be useful in selected patients
with ischemic/thrombotic events while compliant with a clopidogrel
regimen.
Clinical utility not rigorously established but less likely to be
necessary given lesser degree of variation in response.
Genotyping Identifies patients with a diminished (CYP2C19 *2,*3 alleles) or enhanced
(CYP2C17 allele) ability to form active metabolite. Role of genotyping in
clinical management not rigorously established.
Clinical utility not rigorously established but less likely to be
necessary given lesser degree of variation in response.
Risk of bleeding Standard dosing with clopidogrel is associated with less bleeding than with
prasugrel. Higher doses of clopidogrel are associated with greater risk of
bleeding than standard dose clopidogrel.
Risk of spontaneous, instrumented, and fatal bleeds higher with
prasugrel compared with standard dose clopidogrel.
Transition to elective
or nonurgent surgery
Wait at least 5 d after last dose. Wait at least 7 d after last dose.
DES indicates drug-eluting stent; PCI, percutaneous coronary intervention; PPI, proton pump inhibitor; TIA, transient ischemic attack; and UA/NSTEMI, unstable
gina/non-ST–elevation myocardial infarction.
Aintervention; STEMI, ST-elevation myocardial infarction; UA/NSTEMI, unstable angina/no
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ticoagulant with Factor IIa activity, for example, unfractionated heparin.
iography is selected, see STEMI guidelines (147).
s) is a Class IIb, LOE: B recommendation for selected high-risk patients.
protein; IV, intravenous; LOE, level of evidence; PCI, percutaneous coronary
n–ST-elevation myocardial infarction; and UFH, unfractionated heparin.ppendix 6. Flowchart for Class I and Class IIa Recommendations for
*If fondaparinux is used (Class I, LOE: B), it must be coadministered with another an
†Timing of invasive strategy generally is assumed to be 4 to 48 h. If immediate ang
‡Precatheterization triple-antiplatelet therapy (ASA, clopidogrel, glycoprotein inhibitor
ASA indicates aspirin; CABG, coronary artery bypass graft; D/C, discontinue; GP, glyco
Appendix 7. Summary Table
Study Aim of Study Study Size
Patient Population Inclusion and Exclusion
Criteria Endpoints Statistical Analysis Reported p Value (95% CI) OR/HR/RR Conclusion
CURRENT-OASIS 7
(96);
Mehta et al
To evaluate whether doubling the dose
of loading and initial maintenance
doses of clopidogrel is superior to the
standard-dose clopidogrel regimen and
to investigate if higher-dose ASA is
superior to lower-dose ASA. Patients
were assigned in a 22 factorial
design to 600 mg of clopidogrel
loading on Day 1, followed by 150
mg/d for 6 d, then 75 mg thereafter
versus 300 mg clopidogrel loading on
Day 1, followed by 75 mg/d thereafter
and either ASA 300–325 mg/d versus
lower-dose ASA 75–100 mg/d.
25,086 Inclusion criteria: Age 18 y with non–
ST-segment ACS or STEMI. Requirements
included ECG changes compatible with
ischemia or elevated cardiac biomarkers
and coronary angiographic assessment,
with plan to perform PCI as early as
possible but no later than 72 h after
randomization.
Exclusion criteria: Increased risk of or
known bleeding and allergy to clopidogrel
or ASA.
Primary outcome was
CV death, MI, or
stroke, whichever
occurred first, at 30 d.
Prespecified secondary
endpoint was definite
or probable stent
thrombosis (by ARC
definition) in patients
who underwent PCI.
Main safety outcome
was major bleeding
according to trial
criteria.
Primary outcome for clopidogrel dose comparison:
4.2% in double-dose clopidogrel group versus
4.4% in standard-dose clopidogrel group.
0.030 (0.83 to 1.06) HR: 0.94 This analysis of the overall trial
in 25,086 patients failed to
demonstrate a significant
difference in the primary
endpoint of CV death, MI, or
stroke at 30 d between the
double-dose clopidogrel for 7 d
versus standard-dose
clopidogrel and between the
higher-dose versus lower-dose
aspirin subgroups. The
secondary endpoint of definite
stent thrombosis in those
undergoing PCI was reduced in
the clopidogrel higher-dose
group for both DES versus
non-DES subtypes, but this
benefit was offset by increased
major bleeding in the higher-
dose clopidogrel group.
Major bleeding for clopidogrel dose comparison:
2.5% in double-dose clopidogrel group versus
2.0% in standard-dose clopidogrel group.
0.01 (1.05 to 1.46) HR: 1.24
Primary outcome for ASA dose comparison: 4.2%
in higher-dose ASA group versus 4.4% in lower-
dose ASA group.
0.47 (0.86 to 1.09) HR: 0.97
Major bleeding for ASA comparison: 2.3% in
higher-dose ASA group versus 2.3% in lower-
dose ASA group.
0.90 (0.84 to 1.17) HR: 0.99
Clopidogrel and ASA dose interaction—primary
outcome for patients on higher-dose ASA: 3.8% in
double-dose clopidogrel versus 4.6% in standard-
dose clopidogrel.
0.03 (0.69 to 0.98) HR: 0.82
Clopidogrel and ASA dose interaction—primary
outcome for patients on lower-dose ASA: 4.5% in
double-dose clopidogrel versus 4.2% in standard-
dose clopidogrel.
0.46 (0.90 to 1.26) HR: 1.07
Stent thrombosis in patients who underwent PCI:
1.6% with double-dose clopidogrel versus 2.3%
with standard-dose clopidogrel.
0.001 (0.55 to 0.85) HR: 0.68
CURRENT-OASIS 7
(28);
Mehta et al
The goal of this prespecified subgroup
analysis of CURRENT-OASIS 7 (96)
was to examine efficacy and safety
outcomes in patients who underwent
PCI.
17,263 Inclusion criteria: Patients with ACS
(with or without ST-segment elevation)
and either ECG evidence of ischemia or
elevated biomarkers. Patients were
required to have coronary angioplasty
with intent to undergo PCI as early as
possible but not later than 72 h after
randomization.
Exclusion criteria: Increased risk of
bleeding or active bleeding. Additional
information on study eligibility criteria in
study Web appendix.
Primary outcome was
composite of CV death,
MI, or stroke from
randomization to Day
30. Secondary
outcomes included
primary outcome plus
recurrent ischemia,
individual components
of composite
outcomes, and stent
thrombosis per ARC
criteria.
Primary outcome in clopidogrel dose comparison
reduced with double-dose clopidogrel: 3.9% in
double-dose clopidogrel group versus 4.5% in
standard-dose clopidogrel group.
0.039 (0.74 to 0.99) Adjusted
HR: 0.86
This substudy of CURRENT-
OASIS-7 analyzed the 69% of
patients (n17,263) who
underwent PCI, a prespecified
analysis in a postrandomization
subset. In this PCI subgroup,
the primary outcome of CV
death, MI, or stroke at 30 d
was reduced in those
randomized to higher-dose
clopidogrel, and this was
largely driven by a reduction in
myocardial (re)infarction.
Definite stent thrombosis also
was reduced in the higher
clopidogrel dose group with
consistent results across DES
versus non-DES subtypes.
Outcomes were not
significantly different by ASA
dose. Major bleeding was
more common with higher-
dose clopidogrel but not with
higher-dose ASA.
Secondary outcome (CV death, MI, stroke, or
recurrent ischemia) in clopidogrel dose
comparison was reduced with double-dose
clopidogrel: 4.2% in double-dose clopidogrel
versus 5.0% in standard-dose clopidogrel.
0.025 (0.74 to 0.98) HR: 0.85
Rates of definite stent thrombosis were lower with
double-dose clopidogrel (0.7%) versus standard-
dose clopidogrel (1.3%).
0.0001 (0.39 to 0.74) HR: 0.54
CURRENT-defined major bleed was more common
with double-dose (0.1%) than standard-dose
clopidogrel (0.04%); however, no difference in
TIMI-defined severe or major bleeding.
0.16 (0.71 to 7.49) HR: 2.31
(Continued)
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Study Aim of Study Study Size
Patient Population Inclusion and Exclusion
Criteria Endpoints Statistical Analysis Reported p Value (95% CI) OR/HR/RR Conclusion
TIMACS (38);
Mehta et al
To study efficacy of an early invasive
strategy (within 24 h of presentation)
compared with delayed invasive
strategy (any time 36 h after
presentation).
3,031 Inclusion criteria: Presentation to a
hospital with UA or MI without ST-
segment elevation within 24 h after onset
of symptoms and if 2 of the following 3
criteria for increased risk are present: age
60 y, cardiac biomarkers above ULN,
or results on ECG compatible with
ischemia (i.e., ST-segment depression
1 mm or transient ST-segment
elevation or T-wave inversion 3 mm).
Exclusion criteria: Patient who is not a
suitable candidate for revascularization.
Composite of death,
MI, or stroke at 6 mo.
At 6 mo, the primary outcome occurred in 9.6%
of patients in early intervention group versus
11.3% of delayed-intervention group.
0.15 (0.68 to 1.06) HR: 0.85 TIMACS initially targeted
enrollment of 4000 patients
but terminated enrollment at
3031 patients due to
recruitment challenges, limiting
its power. For the overall trial
population, there was only a
nonsignificant trend to a
reduction in the primary
ischemic endpoint in the early
compared with delayed
intervention groups. The
prospectively defined
secondary endpoint of death,
MI, or refractory ischemia was
reduced by early intervention,
mainly because of a reduction
in refractory ischemia.
Heterogeneity was observed in
the primary ischemic endpoint
by a prespecified estimate of
baseline risk according to the
GRACE score, with patients in
the highest tertile experiencing
a sizeable risk reduction and
suggesting a potential
advantage of early
revascularization in this high-
risk subgroup.
28% risk reduction in secondary outcome of
death, MI, or refractory ischemia in early
intervention group (9.5%) versus delayed-
intervention group (12.9%).
0.003 (0.58 to 0.89) HR: 0.72
Prespecified analyses indicated early intervention
improved the primary outcome in the third of
patients at highest risk.
0.06 (0.48 to 0.89) HR: 0.65
Prespecified analyses did not show that early
intervention improved primary outcome in the two
thirds at low to intermediate risk.
0.48 (0.81 to 1.56) HR: 1.12
CARE (165);
Solomon et al
To compare iopamidol and iodixanol in
patients with CKD (eGFR 20–59 mL/
min) who underwent cardiac
angiography or PCI.
482 Inclusion criteria: Men and women
(18 y) with moderate to severe CKD
scheduled for diagnostic cardiac
angiography or PCI.
Exclusion criteria: Pregnancy, lactation,
administration of any investigational drug
within the previous 30 d, intra-arterial or
IV administration of iodinated CM from 7d
before to 72 h after administration of the
study agents, medical conditions or
circumstances that would have
substantially decreased chance to obtain
reliable data (NYHA class IV CHF,
hypersensitivity to iodine-containing
compounds, hyperthyroidism or thyroid
malignancies, uncontrolled DM, unstable
renal drug dependence, psychiatric
disorders, dementia), administration of
any medication to prevent CIN other than
N-acetylcysteine, or intake of nephrotoxic
medications from 24 h before to 24 h
after administration of the study agent.
Primary endpoint was
postdose SCr increase
of 0.5 mg/dL (44.2
mol/L) over baseline.
Secondary outcome
was postdose SCr
increase 25%, a
postdose estimated
GFR decrease 25%,
and mean peak
change in SCr.
In 414 patients, contrast volume, presence of DM,
use of N-acetylcysteine, mean baseline SCr, and
eGFR were comparable in the 2 groups. SCr
increases of 0.5 mg/dL occurred in 4.4% (9 of
204 patients) after use of iopamidol and 6.7% (14
of 210 patients) after iodixanol.
0.39 (6.7 to 2.1) In this randomized trial of
moderate size, the rate of CIN
in higher-risk patients with
moderate CKD was not
significantly different between
the low-osmolar contrast
medium iopamidol and the
iso-osmolar contrast medium
iodixanol.
Rates of SCr increases 25% were 9.8% with
iopamidol and 12.4% with iodixanol.
0.44 (8.6 to 3.5)
In patients with DM, SCr increases to 0.5 mg/
dL were 5.1% (4 of 78 patients) with iopamidol
and 13% (12 of 92 patients) with iodixanol.
0.11
In patients with DM, SCr increases 25% were
10.3% with iopamidol and 15.2% with iodixanol.
0.37
Mean post-SCr increases were significantly less
with iopamidol (all patients: 0.07 mg/dL with
iopamidol versus 0.12 mg/dL with iodixanol).
0.03
In patients with DM, SCr change from baseline
was 0.07 mg/dL with iopamidol versus 0.16 mg/
dL with iodixanol.
0.013
Decreases in eGFR 25% were recorded in 5.9%
(12 patients) with iopamidol and 10% (21
patients) with iodixanol.
0.15 (9.3 to 1.1)
(Continued)
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Study Aim of Study Study Size
Patient Population Inclusion and Exclusion
Criteria Endpoints Statistical Analysis Reported p Value (95% CI) OR/HR/RR Conclusion
Relative renal
safety of
iodixanol
compared
with LOCM
(167); Reed
et al
Meta-analysis to compare
nephrotoxicity of the iso-osmolar
contrast medium iodixanol with LOCM.
16 trials (2763
subjects)
Patients enrolled in RCTs that compared
incidence of CI-AKI with either iodixanol
or LOCM.
Primary endpoint was
incidence of CI-AKI.
Secondary endpoints
were need for renal
replacement therapy
and mortality.
No significant difference in incidence of CI-AKI in
iodixanol group than in LOCM group (overall
summary).
0.19 (0.56 to 1.12) Summary
RR: 0.79
In this updated meta-analysis
of 16 CIN trials, data
supporting a reduction in CIN
favoring the iso-osmolar
medium iodixanol compared
with LOCM were no longer
significant. Subanalyses
suggested potential variations
in relative renal safety by
specific LOCM with reductions
in CIN for iodixanol compared
with the ionic LOCM ioxaglate
and with iohexol, a nonionic
LOCM, but not with 4 other
LOCM.
CI-AKI was reduced when iodixanol was
compared with ioxaglate
0.022 (0.37 to 0.92) RR: 0.58
and when iodixanol was compared with iohexol, (0.07 to 0.56) RR: 0.19
but no difference was noted when iodixanol was
compared with iopamidol,
0.55 (0.66 to 2.18) RR: 1.20
iodixanol was compared with iopromide, 0.84 (0.47 to 1.85) RR: 0.93
or iodixanol was compared with ioversol. 0.68 (0.60 to 1.39) RR: 0.92
No significant difference between iodixanol and
LOCM noted in rates of postprocedure
hemodialysis.
0.20 (0.08 to 1.68) RR: 0.37
No significant difference between iodixanol and
LOCM in rates of death.
0.663 (0.33 to 5.79) RR: 1.38
Nephrotoxicity of
iso-osmolar
iodixanol
compared
with
nonionic
low-osmolar
contrast
(168);
Heinrich et al
Meta-analysis of RCTs to compare
nephrotoxicity of iso-osmolar iodixanol
with nonionic LOCM.
25 trials (3270
subjects)
Inclusion criteria: RCTs analyzing SCr
levels before and after intravascular
application of iodixanol or LOCM.
Incidence of CIN and
change in SCr levels.
Iodixanol did not significantly reduce risk of CIN
(or risk of SCr increase) compared with LOCM
overall. However, risk of intra-arterial iohexol was
greater than that of iodixanol.
0.10 (0.61 to 1.04) RR: 0.80 In this contemporary meta-
analysis of 25 trials, the
incidence of CIN was similar
for a pooled comparison of all
nonionic LOCM other than
iohexol and for the iso-osmolar
medium iodixanol, indicating
equivalent safety for these 2
classes of CM.
No significant risk reduction after IV administration
of CM.
0.79 (0.62 to 1.89) RR: 1.08
In patients with intra-arterial administration and
renal insufficiency, risk of CIN was greater for
iohexol than for iodixanol.
0.01 (0.21 to 0.68) RR: 0.38
No difference between iodixanol and the other
(noniohexol) LOCM.
0.86 (0.50 to 1.78) RR: 0.95
EARLY-ACS (37);
Giugliano et al
To evaluate upstream use of GP IIb/IIIa
inhibitor eptifibatide versus provisional
eptifibatide administration in the
catheterization lab in high-risk patients
with NSTE ACS.
9,492 Inclusion criteria: Patients at least 18 y
of age were randomized within 8–12 h
after presentation and assigned to an
invasive treatment strategy no sooner
than the next calendar day. To qualify as
having a high-risk UA/NSTEMI, patients
were required to have at least 2 of the
following: ST-segment depression or
transient ST elevation, elevated biomarker
levels (CK-MB or troponin), and age 60
y. The study protocol was later amended
to permit enrollment of patients 50–59 y
of age with elevated cardiac biomarker
levels and documented vascular disease
and clarified the timing of angiography as
12 h after randomization.
Exclusion criteria: Increased risk of
bleeding, allergy to heparin or
eptifibatide, pregnancy, renal dialysis
within previous 30 d, intention of
investigator to use a nonheparin
anticoagulant, recent use of a GP IIb/IIIa
inhibitor, and any other condition that
posed increased risk.
The primary efficacy
composite endpoint
was death of any
cause, MI, recurrent
ischemia requiring
urgent
revascularization, or
thrombotic bailout at
96 h. The secondary
efficacy endpoint was
composite of death of
any cause or MI within
the first 30 d. Safety
endpoints included
rates of hemorrhage,
transfusion, surgical
reexploration, stroke,
thrombocytopenia, and
serious adverse events
at 120 h after
randomization.
The primary endpoint was less in the early-
eptifibatide group (9.3%) versus the delayed-
eptifibatide group (10%).
0.23 (0.80 to 1.06) OR: 0.92 In the setting of frequent early
(precatheterization) use of
clopidogrel, the administration
of early, routine eptifibatide
(double-bolus and infusion) did
not achieve statistically
significant reductions in
ischemic events at 96 h (i.e.,
8%, primary endpoint) and
30 d (i.e., 11%, secondary
endpoint) compared with
provisional administration of
eptifibatide, given after
angiography but before PCI.
Early, routine eptifibatide was
associated with a greater risk
of bleeding. No significant
interactions were noted
between efficacy endpoints
and prespecified baseline
characteristics.
At 30 days, the rate of death or MI was 11.2% in
the early-eptifibatide group versus 12.3% in the
delayed-eptifibatide group.
0.08 (0.79 to 1.01) OR: 0.89
Patients in the early-eptifibatide group
experienced higher TIMI major hemorrhage
compared with the delayed-eptifibatide group
(2.6% versus 1.8%, respectively), higher rates of
moderate GUSTO bleeding (6.8% in the early-
eptifibatide group versus 4.3% in the delayed-
eptifibatide group; p0.001), less severe GUSTO
bleeding (0.8% early-eptifibatide group versus
0.9% in delayed-eptifibatide group; p0.97), and
need for red-cell transfusion was increased in the
early-eptifibatide group compared with the
delayed-eptifibatide group (8.6% versus 6.7%,
respectively; p0.001).
0.02 OR: 1.42;
95% CI:
1.07 to
1.89
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Appendix 7. Continued
Study Aim of Study Study Size
Patient Population Inclusion and Exclusion
Criteria Endpoints Statistical Analysis Reported p Value (95% CI) OR/HR/RR Conclusion
ABOARD (120);
Montalescot
et al
To determine if immediate intervention
on admission can result in reduction of
MI versus delayed intervention.
252 Inclusion criteria: Presence of at least 2
of the following: ischemic symptoms,
ECG abnormalities in at least 2
contiguous leads, or positive troponin,
TIMI risk score 3.
Exclusion criteria: Hemodynamic or
arrhythmic instability requiring urgent
catheterization, chronic oral
anticoagulation, or thrombolytic therapy in
the preceding 24 h.
Primary endpoint was
peak troponin value
during hospitalization.
Secondary endpoints
were composite of
death, MI, or urgent
revascularization at
1-mo follow-up.
No difference was found in peak troponin-I
between groups (median 2.1 versus 1.7 mg/mL in
immediate- and delayed-intervention groups,
respectively).
0.79 Immediate (at a median of 70
min) versus delayed (at a
median of 21 h) angiography
and revascularization in UA/
NSTEMI patients conferred no
advantage with regard to the
primary endpoint (myocardial
necrosis by TnI), nor did it
result in even a trend toward
improved outcome in the
clinical secondary endpoint of
death, MI, or urgent
revascularization by 1 mo.
Secondary endpoint was seen in 13.7% (95% CI:
8.6% to 18.8%) of immediate-intervention group
and 10.2% (95% CI: 5.7% to 14.6%) of delayed-
intervention group. The other endpoints did not
differ between the 2 strategies.
0.31
TRITON-TIMI 38
(22); Wiviott
et al
To evaluate treatment with prasugrel
compared with clopidogrel among
patients undergoing planned PCI for
ACS.
13,608 Inclusion criteria: Scheduled PCI for
ACS. For UA/NSTEMI patients, ischemic
symptoms 10 min within 72 h of
randomization, TIMI risk score 3, and
either ST-segment deviation 1 mm or
elevated cardiac biomarker of necrosis.
For STEMI patients, symptom onset
within 12 h of randomization if primary
PCI was scheduled or within 14 d if
medically treated for STEMI.
Exclusion criteria: Included increased
bleeding risk, anemia, thrombocytopenia,
intracranial pathology, or use of any
thienopyridine within 5 d.
Primary endpoints
were death of CV
causes, nonfatal MI, or
nonfatal stroke. Key
safety endpoint was
major bleeding.
Primary endpoint was significantly lower in
prasugrel group compared with clopidogrel group
(9.9% versus 12.1%, respectively).
0.001 (0.73 to 0.90) HR: 0.81 TRITON-TIMI-38 compared the
new thienopyridine prasugrel to
clopidogrel in 13,608
moderate- to high-risk STEMI
and NSTEMI patients
scheduled to undergo PCI.
Prasugrel was associated with
a reduction in the composite
ischemic event rate over 15
mo of follow-up, including
stent thrombosis, but it was
associated with a significantly
increased rate of bleeding. In
subgroup analyses, those with
prior stroke/TIA fared worse on
prasugrel, and no advantage
was seen in those 75 y of
age or 60 kg in weight.
Primary endpoint was similar in UA/NSTEMI cohort
(9.9% with prasugrel versus 12.1% with
clopidogrel; 18% RR).
0.002 (0.73 to 0.93) HR: 0.82
Primary endpoint in STEMI cohort (10% in
prasugrel versus 12.4% in clopidogrel; 21% RR).
0.02 (0.65 to 0.97) HR: 0.79
Efficacy benefit evident by 3 d (4.7% in prasugrel
group versus 5.6% in clopidogrel group).
0.01 (0.71 to 0.96) HR: 0.82
Efficacy benefit from Day 3 to end of follow-up
(5.6% in patients receiving prasugrel versus 6.9%
of patients receiving clopidogrel).
0.003 (0.70 to 0.93) HR: 0.80
Definite or probable stent thrombosis occurred
less frequently in prasugrel group than in
clopidogrel group (1.1% versus 2.4%,
respectively).
0.001 (0.36 to 0.64) HR: 0.48
Safety endpoint of TIMI major non-CABG bleeding
was higher with prasugrel compared with
clopidogrel (2.4% versus 1.8%, respectively).
0.03 (1.03 to 1.68) HR: 1.32
Increase in bleeding consistent for different
categories of TIMI major bleeding, including life-
threatening bleeding (1.4% in prasugrel versus
0.9% in clopidogrel; HR: 1.52; 95% CI: 1.08 to
2.13; p0.01), fatal bleeding (0.4% in prasugrel
versus 0.1% in clopidogrel; HR: 4.19; 95% CI:
1.58 to 11.11; p0.002), and nonfatal bleeding
(1.1% in prasugrel versus 0.9% in clopidogrel;
HR: 1.25; 95% CI: 0.87 to 1.81; p0.23).
CABG-related TIMI major bleeding increased with
prasugrel compared with clopidogrel (13.4%
versus 3.2%, respectively).
0.001 (1.90 to 11.82) HR: 4.73
No difference in mortality (death of any cause)
between groups (3.0% in prasugrel group versus
3.2% in clopidogrel group).
0.64 (0.78 to 1.16) HR: 0.95
Net clinical benefit endpoint (composite of death,
MI, stroke or TIMI major bleeding) favored
prasugrel over clopidogrel (12.2% versus 13.9%,
respectively).
0.004 (0.79 to 0.95) HR: 0.87
(Continued)
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Appendix 7. Continued
Study Aim of Study Study Size
Patient Population Inclusion and Exclusion
Criteria Endpoints Statistical Analysis Reported p Value (95% CI) OR/HR/RR Conclusion
SWEDEHEART
(161);
Szummer et al
To describe distribution of CKD and
use of early revascularization, as well
as to determine if an invasive
approach is associated with lower
mortality at every level of renal
function.
23,262 Inclusion criteria: NSTEMI patients 80
y of age from nationwide CCU register
(2003 and 2006).
Description of 1-y
survival according to
renal function stage.
Patients treated with early revascularization had
overall improved survival rate at 1 y.
0.001 (0.56 to 0.73) HR: 0.64 A contemporary nationwide
Swedish registry, evaluated the
use of early revascularization
after NSTEMI across all stages
of CKD, and stratified
outcomes by stage of CKD.
Early revascularization was
associated with improved
adjusted 1-y survival in UA/
NSTEMI patients with mild-to-
moderate CKD, but no
association was observed in
those with severe and end-
stage disease. SWEDEHEART is
limited by its observational
nature, but by capturing
unselected patients, it may be
quite reflective of real-world
experience.
1-y mortality for patients with eGFR 90: 1.9%
for invasive treatment versus 10% for medical
treatment.
0.001 (0.42 to 0.80) HR: 0.58
1-y mortality for patients with eGFR 60 to 89:
2.4% for invasive treatment versus 10% for
medical treatment.
0.001 (0.52 to 0.80) HR: 0.64
1-y mortality for patients with eGFR 30 to 59: 7%
for invasive treatment versus 22% for medical
treatment.
0.001 (0.51 to 1.61) HR: 0.91
1-y mortality for patients with eGFR 15 to 29:
22% for invasive treatment versus 41% for
medical treatment.
0.940 (0.51 to 1.61) HR: 0.91
1-y mortality for patients with eGFR 15/dialysis:
44% for invasive treatment versus 53% for
medical treatment.
0.150 (0.84 to 3.09) HR: 1.61
COGENT (108);
Bhatt et al
To investigate efficacy and safety of
concomitant clopidogrel and PPI
administration in patients with CAD
receiving clopidogrel and ASA.
3,761 Inclusion criteria: Age 21 y,
clopidogrel therapy with concomitant ASA
anticipated for at least next 12 mo,
including patients with ACS or coronary
stent placement.
Exclusion criteria: Hospitalized patients
for whom discharge not anticipated
within 48 h of randomization; need for
current/long-term use of PPI, H2-receptor
antagonist, sucralfate, or misoprostol;
erosive esophagitis or esophageal or
gastric variceal disease or previous
nonendoscopic gastric surgery;
clopidogrel or other thienopyridine 21 d
before randomization; receipt of oral
anticoagulant unable to be discontinued
safely; recent fibrinolytic therapy.
Primary GI safety
endpoint: composite of
GI overt or occult
bleeding, symptomatic
gastroduodenal ulcers
or erosions,
obstructions, or
perforation.
Primary CV safety
endpoint: composite of
death of CV causes,
nonfatal MI, coronary
revascularization, or
ischemic stroke.
Total GI event rate: 1.1% with omeprazole versus
2.9% with placebo.
0.001 (0.18 to 0.63) HR: 0.34 In this randomized, placebo
controlled comparison in 3873
patients with an indication for
dual-antiplatelet therapy, no
difference was found in the
primary composite CV endpoint
between clopidogrel plus
omeprazole and clopidogrel
plus placebo at 180 d. The
rate of GI bleeding and
associated complications were
reduced with omeprazole.
Study limitations include
premature termination of
planned enrollment, limited
power to discern small to
moderate differences between
therapies, and the use of a
single-pill formulation, which
might differ in release kinetics
for its 2 components.
Overt upper GI bleeding rate: 0.1% with
omeprazole versus 0.6% with placebo.
0.001 (0.03 to 0.56) HR: 0.13
Total CV event rate: 4.9% with omeprazole versus
5.7% with placebo.
0.96 (0.68 to 1.44) HR: 0.99
ACS indicates acute coronary syndrome; ARC, academic research consortium; ASA, aspirin; CABG, coronary artery bypass graft; CAD, coronary artery disease; CCU, coronary care unit; CHF, congestive heart failure; CI-AKI,
contrast-induced acute kidney injury; CI, confidence interval; CIN, contrast-induced nephropathy; CKD, chronic kidney disease; CK-MB, creatine kinase-MB; CM, contrast media; CURRENT, Clopidogrel optimal loading dose Usage
to Reduce Recurrent EveNTs; CV, cardiovascular; DES, drug-eluting stent; DM, diabetes mellitus; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; GI, gastrointestinal; GP, glycoprotein; GRACE, Global Registry
of Acute Coronary Events; GUSTO, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries trial; HR, hazard ratio; IV, intravenous; LD, loading dose; LOCM, low-osmolar contrast media;
MACCE, major adverse cardiac and cerebrovascular events; MI, myocardial infarction; NSTE, non-ST-elevation; NSTEMI, non–ST-elevation myocardial infarction; NYHA, New York Heart Association; OR, odds ratio; PCI,
percutaneous coronary intervention; PPI, proton pump inhibitor; RCT, randomized controlled trial; RR, relative risk; SCr, serum creatinine; STEMI, ST-elevation myocardial infarction; TIA, transient ischemic attack; TIMI, Thrombolysis
in Myocardial Infarction; TnI, troponin I; UA, unstable angina; and ULN, upper limit of normal.
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